cms.bioaccessla.com

Category: Preparing for First-In-Human Studies

Offers insights and best practices for Medtech, Biopharma, and Radiopharma companies preparing for their first-in-human clinical trials.

  • CRO in Colombia: the first-in-human CRO with a local Colombian entity

    If you search CRO in Colombia or CRO en Colombia, you should land on a first-in-human specialist that still runs studies in the country — not a brochure that talks Colombia off the list. bioaccess® is the First-in-Human CRO. Headquarters are in Miami. Roots, a local legal entity, and an office are in Colombia. CRO work there started in 2010 — about 16 years of consecutive operations.

    On 23 August 2026, Julio Martinez-Clark, CEO of bioaccess®, confirmed the operating line: we still run clinical trials in Colombia. We do not tell sponsors to take new first-in-human work out of the country. INVIMA clocks are real. A local Colombian entity is how we manage them — not a reason to leave.

    What “CRO in Colombia” has to mean

    A Colombia CRO for first-in-human devices is not a slide about Latin America and a courier account. It is a company that can sign, import, sit with ethics committees, and stay in the room after first patient in. That is why the local entity matters.

    • Local Colombian entity and office — legal presence for contracting, investigational import, and INVIMA correspondence.
    • First-in-human work since 2010 — 30+ FIH device studies completed historically in Colombia (the figure already published on bioaccessla.com).
    • 20+ pre-qualified sites in Bogotá, Cali, Medellín, and Barranquilla.
    • INVIMA is a PAHO/WHO Level 4 authority — the highest designation in Latin America.
    • Same time zone as the US East Coast, with direct flights from Miami.

    That combination is the category. Global Phase 1 networks can list Colombia. They rarely hold a Colombian entity built for first-in-human devices. Local monitors can staff a visit. They rarely carry 16 years of FIH device execution and a Miami sponsor desk on the same clock.

    We still run trials in Colombia

    Older public copy on bioaccessla.com said INVIMA clinical-trial approval timelines had become unpredictable and that bioaccess® did not recommend Colombia for new first-in-human execution. That line is withdrawn.

    The facts that stay true: INVIMA review can move, stall, or ask again. First-in-human programs need a start date someone owns. The correction is operational, not geographic. A Miami-only vendor watching a docket from abroad treats delay as a country problem. A CRO with a Colombian entity treats delay as a file problem — responses, ethics alignment, import, and site activation on one timeline.

    bioaccess® is still enrolling and still activating work in Colombia. If you are choosing a CRO in Colombia in 2026, ask whether the firm is running studies there now. We are.

    How a local entity manages INVIMA clocks

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) issues the clinical-trial permit for investigations. Ethics review sits with the site’s comité de ética. Those clocks are not a reason to abandon Colombia. They are the reason to hire a CRO that already lives inside them.

    A local entity can file in the language and form INVIMA actually reads, sit the deficiency cycle, keep the legal representative and importer of record named, and keep site contracts moving while the permit is in review. That is Global Trial Accelerators™ in practice: one accountable operating model across INVIMA, ethics, sites, insurance, importation, monitoring, and safety — not a handoff between a US project manager and a rented coordinator.

    We will not invent a median day-count here. Sponsors should ask for a study-specific calendar. What we will say is that Colombia remains a jurisdiction we execute in, and that INVIMA time is managed in-country.

    Sites: Bogotá, Cali, Medellín, Barranquilla

    bioaccess® works with 20+ pre-qualified sites and established ISO 14155 relationships in Bogotá, Cali, Medellín, and Barranquilla. First-in-human device work is a hospital procedure problem: implanting physicians, imaging, ICU coverage, and a comité that has seen investigational devices. The site list is Colombian. The sponsor desk is on US Eastern time.

    INVIMA commercial registration is a second, live service

    Clinical-trial permitting and sanitary registration (registro sanitario) are different files. bioaccess® still delivers both in Colombia.

    • Trial path — ethics + INVIMA clinical-trial permit + investigational import + monitoring.
    • Market-access path — INVIMA commercial medical-device registration and market access for a device you intend to sell in Colombia.

    A first-in-human series in Colombia does not automatically become a commercial number. A commercial number does not replace a trial permit. Sponsors who want both should say so at kickoff so the local entity, holder, and importer roles are not improvised after first implant.

    Why Miami HQ and Colombian roots in the same sentence

    US sponsors run board and FDA conversations on Eastern time. Colombia is on that clock. Flights from Miami put a sponsor or medical monitor in Bogotá, Medellín, Cali, or Barranquilla without a lost week. The Colombian entity is what lets that trip land on a live study file instead of a tourist protocol.

    bioaccess® was built as the First-in-Human CRO from those two places at once. The Colombia CRO identity is not a country page we keep for nostalgia. It is current operations.

    Questions a sponsor should ask any CRO in Colombia

    1. Do you have a local Colombian entity, or only a correspondent?
    2. Are you running clinical trials in Colombia now — not “historically”?
    3. How many first-in-human device studies have you completed in Colombia?
    4. Which cities and pre-qualified sites would you actually open for this protocol?
    5. Who owns the INVIMA clock when the file sits — Miami, or the local entity?
    6. Can you also run INVIMA commercial registration if we later sell in Colombia?

    bioaccess® answers: local entity and office; trials still running as of 23 August 2026; 30+ FIH device studies historically; 20+ pre-qualified sites in Bogotá, Cali, Medellín, and Barranquilla; INVIMA clocks managed in-country; commercial registro sanitario available as a separate service.

    FDA use of Colombian first-in-human data

    Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics review and informed consent. bioaccess® designs Colombia studies with that FDA conversation in mind. Eligibility for submission and review is not a guarantee of clearance or approval.

    How to start

    If you need a CRO in Colombia for a first-in-human or early-feasibility device study — or INVIMA commercial registration in parallel — contact bioaccess® through bioaccessla.com/contact. Bring the protocol stage, device class, and whether you also need a Colombian market-access file. We will tell you how the local entity would run the clocks. We will not tell you to leave the country.

  • CRO en Colombia: la CRO de first-in-human con entidad local colombiana

    Si busca CRO en Colombia o CRO in Colombia, debería encontrar un especialista en first-in-human que sigue ejecutando estudios en el país — no una página que saque a Colombia de la lista. bioaccess® es the First-in-Human CRO. La sede está en Miami. Las raíces, la entidad legal local y la oficina están en Colombia. El trabajo de CRO aquí empezó en 2010: unos 16 años de operación continua.

    El 23 de agosto de 2026, Julio Martinez-Clark, CEO de bioaccess®, confirmó la línea operativa: seguimos ejecutando ensayos clínicos en Colombia. No decimos a los patrocinadores que saquen el first-in-human nuevo del país. Los tiempos de INVIMA son reales. Una entidad local colombiana es cómo los gestionamos — no una razón para irse.

    Qué tiene que significar “CRO en Colombia”

    Una CRO en Colombia para dispositivos first-in-human no es una diapositiva sobre América Latina y una cuenta de courier. Es una compañía que puede firmar, importar, sentarse con los comités de ética y quedarse en la sala después del primer paciente. Por eso importa la entidad local.

    • Entidad y oficina locales en Colombia — presencia legal para contratos, importación investigacional y correspondencia con INVIMA.
    • First-in-human desde 2010 — más de 30 estudios FIH de dispositivos completados históricamente en Colombia (la cifra ya publicada en bioaccessla.com).
    • Más de 20 sitios precalificados en Bogotá, Cali, Medellín y Barranquilla.
    • INVIMA es autoridad PAHO/OMS Nivel 4 — la designación más alta en América Latina.
    • Misma zona horaria que la Costa Este de EE. UU., con vuelos directos desde Miami.

    Esa combinación es la categoría. Las redes globales de Fase 1 pueden listar Colombia. Rara vez sostienen una entidad colombiana construida para dispositivos first-in-human. Un monitor local puede cubrir una visita. Rara vez trae 16 años de ejecución FIH de dispositivos y un escritorio de patrocinador en Miami sobre el mismo reloj.

    Seguimos ejecutando ensayos en Colombia

    Había copy público anterior en bioaccessla.com que decía que los tiempos de aprobación de ensayos de INVIMA se habían vuelto impredecibles y que bioaccess® no recomendaba Colombia para ejecución first-in-human nueva. Esa línea queda retirada.

    Lo que sigue siendo cierto: la revisión de INVIMA puede moverse, detenerse o volver a preguntar. Un programa first-in-human necesita una fecha de inicio con dueño. La corrección es operativa, no geográfica. Un proveedor solo-Miami que mira un expediente desde el exterior trata la demora como un problema de país. Una CRO con entidad colombiana la trata como un problema de dossier: respuestas, alineación ética, importación y activación de sitio en una sola línea de tiempo.

    bioaccess® sigue enrolando y sigue activando trabajo en Colombia. Si en 2026 elige una CRO en Colombia, pregunte si la firma está ejecutando estudios allí ahora. Nosotros sí.

    Cómo una entidad local gestiona los relojes de INVIMA

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) emite el permiso de ensayo clínico. La ética vive en el comité de ética del sitio. Esos relojes no son motivo para abandonar Colombia. Son el motivo para contratar una CRO que ya vive dentro de ellos.

    Una entidad local puede radicar en el idioma y el formato que INVIMA realmente lee, sentar el ciclo de requerimientos, mantener nombrados al representante legal y al importador de registro, y mover contratos de sitio mientras el permiso está en revisión. Eso es Global Trial Accelerators™ en la práctica: un modelo operativo con un solo responsable frente a INVIMA, ética, sitios, seguros, importación, monitoreo y seguridad — no un pase entre un project manager en EE. UU. y un coordinador alquilado.

    No vamos a inventar aquí una mediana de días. El patrocinador debe pedir un calendario del estudio. Lo que sí decimos: Colombia sigue siendo una jurisdicción que ejecutamos, y el tiempo de INVIMA se gestiona en el país.

    Sitios: Bogotá, Cali, Medellín, Barranquilla

    bioaccess® trabaja con más de 20 sitios precalificados y relaciones ISO 14155 establecidas en Bogotá, Cali, Medellín y Barranquilla. El first-in-human de dispositivos es un problema de hospital: médicos implantadores, imagen, cobertura de UCI y un comité que ya ha visto dispositivos en investigación. La lista de sitios es colombiana. El escritorio del patrocinador está en horario del Este de EE. UU.

    El registro comercial INVIMA es un segundo servicio vigente

    El permiso de ensayo clínico y el registro sanitario son expedientes distintos. bioaccess® sigue entregando ambos en Colombia.

    • Ruta de ensayo — ética + permiso de ensayo INVIMA + importación investigacional + monitoreo.
    • Ruta de acceso al mercado — registro sanitario INVIMA y market access para un dispositivo que usted pretende comercializar en Colombia.

    Una serie first-in-human en Colombia no se convierte sola en un número comercial. Un número comercial no sustituye un permiso de ensayo. Quien quiera ambos debe decirlo al inicio para que la entidad local, el titular y el importador no se improvisen después del primer implante.

    Por qué Miami y raíces colombianas van en la misma frase

    Los patrocinadores de EE. UU. corren junta y conversación FDA en horario del Este. Colombia está en ese reloj. Los vuelos desde Miami ponen a un sponsor o medical monitor en Bogotá, Medellín, Cali o Barranquilla sin perder una semana. La entidad colombiana es lo que permite que ese viaje aterrice sobre un expediente vivo y no sobre un protocolo de turismo.

    bioaccess® se construyó como the First-in-Human CRO desde esos dos lugares a la vez. La identidad de CRO en Colombia no es una página de país por nostalgia. Es operación actual.

    Preguntas que un patrocinador debe hacer a cualquier CRO en Colombia

    1. ¿Tiene entidad local colombiana, o solo un corresponsal?
    2. ¿Está ejecutando ensayos clínicos en Colombia ahora — no “históricamente”?
    3. ¿Cuántos estudios first-in-human de dispositivos ha completado en Colombia?
    4. ¿Qué ciudades y sitios precalificados abriría para este protocolo?
    5. ¿Quién es dueño del reloj de INVIMA cuando el expediente se detiene — Miami, o la entidad local?
    6. ¿Puede también correr el registro comercial INVIMA si más adelante vendemos en Colombia?

    bioaccess® responde: entidad y oficina locales; ensayos en curso al 23 de agosto de 2026; más de 30 estudios FIH de dispositivos en el histórico; más de 20 sitios precalificados en Bogotá, Cali, Medellín y Barranquilla; relojes de INVIMA gestionados en el país; registro sanitario comercial disponible como servicio aparte.

    Uso FDA de datos first-in-human generados en Colombia

    Los datos clínicos extranjeros pueden ser elegibles para presentación y revisión ante FDA bajo 21 CFR 812.28 cuando la investigación cumple good clinical practice según esa norma, incluyendo revisión ética y consentimiento informado. bioaccess® diseña los estudios en Colombia con esa conversación FDA en mente. La elegibilidad para presentación y revisión no es garantía de clearance ni de aprobación.

    Cómo empezar

    Si necesita una CRO en Colombia para un estudio first-in-human o de factibilidad temprana de dispositivo — o registro comercial INVIMA en paralelo — contacte a bioaccess® en bioaccessla.com/contact. Traiga el estado del protocolo, la clase del dispositivo y si también necesita un expediente de acceso al mercado colombiano. Le diremos cómo la entidad local correría los relojes. No le diremos que se vaya del país.

  • INVIMA FIH Device Classification in Colombia: Decree 4725 Rules That Decide the Protocol Path

    Most INVIMA first-in-human (FIH) delays I see do not start on the Sala Especializada calendar. They start when regulatory affairs copies a U.S. Class II 510(k) letter into the Colombian file and calls it a classification. Decree 4725 of 2005 does not work that way. The manufacturer classifies the device from intended purpose, duration of body contact, invasiveness, and local versus systemic effect, using the Article 7 rules. The most stringent applicable rule wins. If that call is wrong, the technical concept you are waiting for is the wrong concept.

    This is not the INVIMA sanitary-registration checklist. Registro sanitario / permiso de comercialización is a different operating system — uncontrolled Class I/IIa automatic registration versus controlled IIb/III review, legal representative, CCAA importer, UDI-DI under Resolution 1405 of 2022. This article is the classification decision that decides how an investigational, often unregistered, device enters a human protocol in Colombia.

    What INVIMA means by an investigational device

    Decree 4725 Article 2 defines a “dispositivo médico destinado a investigaciones clínicas” as any medical device to be used by a specialist physician in investigations carried out in an adequate human clinical setting. The same article defines a clinical study as any investigation in human beings intended to discover or verify clinical or other effects of medical devices and/or to identify any adverse reaction, in order to confirm safety and/or effectiveness. A “equipo biomédico prototipo” is equipment still in an experimental phase that has not been used in care or demonstration and that lacks a free-sale certificate from the competent authority in the country of origin.

    Article 36 then draws a hard line sponsors blur: a prototype device or controlled-technology biomedical equipment, national or imported, may be authorized only for research and experimentation and may not be used in health care. Import of such prototypes requires an INVIMA technical concept, in accordance with the health-research rules in force. Article 48(b) is the complementary import valve: INVIMA may exceptionally authorize import of a finished device without a sanitary registration when the Ministry or INVIMA has authorized clinical investigation in the country, after the competent specialized room has issued its concept. Article 55(n) requires labeling to state that the device is specifically for clinical and/or performance investigations before market launch. If your cartons look like a commercial shipment, you have already broken the classification story.

    In vitro diagnostics are carved out of Decree 4725 (Article 1, paragraph 1) and sit on Decree 3770 of 2004. Do not force an IVD performance study into the implant classification box. INVIMA’s device clinical-investigation page publishes separate IVD forms (ASS-RSA-FM082, FM083) for that reason.

    The four classes that actually drive the FIH file

    Article 5 of Decree 4725 is the class rule:

    • Class I — low risk, general controls; not intended to protect or sustain life or for a special use in preventing deterioration of health; no unreasonable potential risk of illness or injury.
    • Class IIa — moderate risk, special manufacturing controls to demonstrate safety and effectiveness.
    • Class IIb — high risk, special design and manufacturing controls to demonstrate safety and effectiveness.
    • Class III — very high risk, special controls; intended to protect or sustain life or for a substantial use in preventing deterioration of health, or presenting a potential risk of illness or injury.

    Article 6 says the rules follow intended purpose. Accessories are classified on their own intended purpose when used with another device. Software that drives or influences a device inherits that device’s class. If the device is not intended mainly for one body site, classify on the most critical specified use. If several rules apply, take the highest class.

    Article 7 is where FIH programs actually break. The rules that recur on first-in-human device boards:

    • Rule 6 / 7 — surgically invasive devices. Transient surgical tools default IIa (reusable instruments can be I). Direct contact with the heart or central circulatory system to diagnose, monitor or correct a defect is Class III even for short use. Direct contact with the central nervous system is Class III for short-term surgical invasives (Rule 7).
    • Rule 8 — implants and long-term surgically invasive devices default IIb, and jump to Class III if they contact heart, central circulation or CNS, exert a biological effect or are largely absorbed, or undergo chemical change in the body / administer a medicinal product (teeth placements excepted).
    • Rule 9–11 — active therapeutic and diagnostic devices, and devices that administer or withdraw substances. “Potentially hazardous” energy or delivery is IIb, not IIa.
    • Rule 13 — a device that incorporates, as an integral part, a substance that would be a medicine if used separately, and that substance has an action ancillary to the device, is Class III.
    • Rule 17 — devices manufactured using non-viable animal tissues or derivatives are Class III unless they contact intact skin only.

    A U.S. “non-significant-risk” or 510(k) Class II label is not a Colombian class. A coronary-contact catheter that someone files as IIa because “it is only diagnostic” is still Rule 6(e) / 7(c) territory if the intended purpose is direct contact with the central circulation. Write the Spanish intended-purpose sentence first. Then apply the rule. Then name the class. If clinical, quality, and the Colombian legal representative cannot repeat those three lines, you are not ready to talk to a Comité de Ética en Investigación (CEI).

    How class changes the investigation path — not the registration path

    INVIMA’s Dirección de Dispositivos Médicos y Otras Tecnologías runs device clinical investigation through GICASE (Grupo de Investigación Clínica y Apoyo a Sala Especializada), reorganized under INVIMA Resolution 2022035262 of 20 September 2022. The Agency’s public clinical-investigation page is the index of live forms. For a prototype / unregistered device protocol, the checklist that actually opens the technical-concept request is ASS-RSA-FM085. The specialized-room request form is ASS-RSA-FM172. The CEI is expected to complete ASS-RSA-FM169 on initial evaluation of a device (or other-technology) clinical study. After authorization, serious adverse events go on ASS-RSA-FM171 and periodic study reports on ASS-RSA-FM170.

    That form set is how class becomes operational. A Class III implant FIH is a prototype investigation: Article 36 technical concept, CEI approval under Resolución 8430 de 1993, and an import path that cites the investigation authorization rather than a DM sanitary-registration number. A Class I/IIa tool that is already registered in Colombia for the same intended purpose is a different conversation — you may still need ethics and institutional authorization under 8430, but you are not pretending the unit is a prototype. A registered device studied for a new intended purpose is a new classification exercise, because Article 6 follows the purpose you will actually use in the protocol, not the purpose on last year’s registro.

    Resolución 8430 de 1993 remains the cross-cutting human-research rule INVIMA cites on that same page. Article 6 requires prior laboratory or animal justification, written informed consent, qualified investigators, and authorization from the legal representative of the researching institution, the institution where the work is done, and the institutional research-ethics committee. Article 11 classifies research by risk to the subject. An FIH implant is not “minimal risk.” Do not file it as if it were.

    Resolución 2378 de 2008 adopts Good Clinical Practice and BPC certification for institutions that conduct drug research. INVIMA’s device page cites it as part of the national research furniture. It is not the device-classification statute and it is not a substitute for FM085. If your chosen hospital’s only certificate is a medicines BPC, ask GICASE and the CEI what they will accept for a device protocol. Do not invent a waiver in a slide.

    What the technical file must prove for the class you claimed

    Decree 4725’s commercial dossier rules are still the evidence language reviewers know. Article 18(j)–(k) is the tell: IIa/IIb/III need scientific information supporting safety and a risk analysis; IIb and III need clinical studies on use to demonstrate safety and effectiveness — for a marketed file. For an FIH, you do not yet have those clinical studies. What you must have is the nonclinical justification 8430 Article 6 demands, a risk-management file that matches the Article 7 rule you applied, biocompatibility and bench data for the tissues and duration you claimed, and an investigator brochure whose “expected” harms match the class. If you classified the device IIb under Rule 8 (implant) and the brochure reads like a Class IIa surgical tool, the specialized room will not fix that with a courtesy question. They will stop the concept.

    ISO 14155 is the device GCP you should run to, especially if the same dataset must later support FDA review of foreign data under 21 CFR 812.28. Decree 4725 does not cite ISO 14155 by name. That is not permission to run an FIH without device accountability, investigational labeling (Article 55(n)), or source documents an inspector can reconstruct.

    Import is a classification problem. Article 36 plus Article 48(b) are how unregistered units enter. Quantities should match the protocol. The importer still needs a lawful storage/conditioning posture — commercially, that is the CCAA world of Articles 10–11. Do not park investigational implants in a spare bedroom because “it is not a registro shipment.”

    Eight lines to lock before CEI submission

    1. Intended purpose in Spanish. The sentence that will appear on FM085, the protocol, the brochure, and later — if you commercialize — on the registro. Changing “long-term implant” to “intraoperative aid” after CEI approval is a new class.
    2. Article 7 rule and Class I / IIa / IIb / III. Record why neighboring rules were rejected. Heart, central circulation, CNS, animal tissue, and ancillary drug substance are the usual missed upgrades.
    3. Prototype versus registered-same-indication versus new-indication-on-a-registered-device. Article 36 applies to prototypes. A new purpose on an old number is not a shortcut.
    4. IVD or device. Decree 3770 versus 4725. Wrong form family wastes a Sala cycle.
    5. CEI path under 8430. Institutional authorization plus FM169. Name the committee that will actually meet.
    6. Technical-concept pack. FM085 + FM172, complete, in the language INVIMA will review. English-only annexes are not a strategy.
    7. Import list. Every SKU, spare, and accessory that will move under Article 36 / 48(b), labeled per Article 55(n).
    8. Safety reporting owners. FM171 for serious events, FM170 for periodic reports. Expectedness language lives in the brochure you classified against.

    This week, run a 90-minute huddle with RA, clinical, quality, and the Colombian legal representative. Put the intended-purpose sentence, the Article 7 rule, the class, and a prototype-versus-registered decision on one page. Attach Decree 4725 Articles 2, 5–7, 36 and 48(b), Resolución 8430 Articles 6 and 11, and the current GICASE form list. If those four people cannot sign the page, do not book first-patient week. The calendar you save is not INVIMA’s. It is the quarter you would have spent unscrewing a class you never locked.

  • Costa Rica FIH Activation Calendar: CEC, CONIS Registration, and the 3% Canon

    Most first-in-human (FIH) calendars I see for Costa Rica start on the wrong clock. Teams treat CONIS as a single “ministry approval” and then wonder why first-patient week slips after ethics is already in the file. Costa Rica is a two-gate country: a CONIS-accredited Comité Ético Científico (CEC) must give written approval before an interventional protocol can start, and the approved project is then registered with the Consejo Nacional de Investigación en Salud (CONIS). Those are different legal acts. If you collapse them, you are not planning activation — you are hoping.

    This is an activation calendar, not another “how to run a trial in Costa Rica” tour. It is written for the RA lead who has to put first-patient-in (FPI) on a board that finance and the FDA pre-sub team will actually use. Ranges below are practitioner planning ranges for 2026 device programs. They are not CONIS service-level agreements.

    The legal stack you actually file against

    The statute is Ley N.° 9234, Ley Reguladora de Investigación Biomédica (in force 25 April 2014; SCIJ current text). Article 1 covers biomedical research with human beings in public and private settings. The law creates CONIS as an independent ethical, technical and scientific body attached to the Ministerio de Salud, with maximum deconcentration. Article 46 lets a public or private entity that hosts research constitute a CEC, provided CONIS accredits it. The same article requires the Ministry of Health to constitute a CEC that is responsible for approving Phase I clinical trials nationally, and for protocols from investigators or entities that do not have their own accredited CEC.

    CONIS’s own CEC page repeats those points and cites the implementing reglamento, Decreto Ejecutivo N.° 39061-S, plus the reform Decreto N.° 39533-S. CONIS’s legislation index also lists the organic reglamento of CONIS (Decreto N.° 40884-S), the 22 September 2020 Gaceta repeal of Article 18 of Ley 9234, the CCSS biomedical-research reglamento for Caja sites, and — on the international list — the ICH E6 addendum, CIOMS, Helsinki, and related instruments. For a medical-device FIH, treat ISO 14155 as the device GCP you will later defend to FDA under 21 CFR 812.28; do not assume a drug ICH E6 binder substitutes for a device investigator brochure and risk-management file.

    Ley 9234 is explicit that a protocol needs written approval from an accredited CEC before it starts, and that if the site is a public health institution the corresponding institutional authority must also authorize the work. No public or private authority may waive that sequence. That is why “we already have a U.S. IRB letter” does not start screening in San José.

    What “Phase I” means for a device FIH

    Decreto 39061-S defines Phase I in drug language: first introduction of a medicine into humans. Device sponsors still get caught by the institutional rule in Ley 9234 Article 46: the Ministry of Health CEC is the national Phase I committee. If your protocol is truly first-in-human — novel energy, a first implant, a first intra-cardiac or CNS contact — plan the ethics path as the Ministry CEC unless CONIS or the accredited committee you asked has confirmed in writing that a site CEC may take it. Guessing here is how a four-week ethics slot becomes a resubmission.

    Independent investigators and entities without a CEC may submit to any CONIS-accredited CEC. Site CECs must be independent of the host and resourced to do the job. CONIS publishes the accredited-CEC list; if your chosen committee is not on it, you do not have an ethics clock.

    The sequential activation calendar

    Build the critical path as gates, not as a single “Costa Rica 60–90 days” slogan. The following is a 14–20 week FPI plan for a complete Spanish dossier at a private site that already has an accredited CEC. Public / CCSS sites add an institutional-authorization lane.

    Weeks 0–3 — lock the Spanish file before anyone books a CEC slot. Protocol, investigator brochure, informed-consent forms, insurance certificate, investigational-device description and risk analysis, manufacturing / sterility story, PI CV and GCP training, site feasibility, and the signed budget that will later support the CONIS canon. Ley 9234 requires the CEC to send CONIS a copy of the signed contract when the project is registered. If the budget in the ethics pack and the budget used for the 3% canon do not match, registration stalls after you thought you were approved.

    Weeks 3–8 — CEC review. Decreto 39061-S Article 44 requires a defined submission package before any experimental, clinical or interventional study starts. Subsequent reforms to that reglamento have treated the CEC pronouncement window as one calendar month counted from the business day after a complete filing. Treat “one month” as the first-cycle target only if the file is complete and the committee does not issue queries. Device FIH files that arrive with an English brochure, an unsigned insurance binder, or a consent that does not match the protocol lose that month. Practitioner planning for a first-in-human implant is 4–8 weeks of ethics time including one query cycle — still faster than a U.S. IDE, still not automatic.

    Weeks 5–10 (parallel, not after CEC). Translate and legalize what CONIS will need to register the approved project. Open the insurance policy to Costa Rican law and local claim service. Start site contracts and the investigational-device import / customs file. Costa Rica does not give you a U.S.-style IDE number that magically clears every carton. Label units as investigational, limit quantity to the protocol, and keep the importer of record aligned with the sponsor entity that will appear on the CONIS register.

    Weeks 8–12 — CONIS registration and the 3% canon. Ley 9234 requires the principal investigator, when registering an approved biomedical-research project, to pay CONIS a sum equal to 3% of the total research budget. Decreto 39061-S (canon provisions, as reformed) makes CONIS responsible for verifying that payment and depositing it to the CONIS collection account. Independent, non-commercial research can be treated differently; a sponsored device FIH is not that case. Do not treat the canon as a “CRO fee.” It is a statutory levy on the study budget at registration of the approved project. Build it into the budget before you sign the site. Registration is not a substitute for CEC approval, and CEC approval is not a substitute for registration.

    Weeks 10–14 — institutional green light and site activation. If the site is CCSS or another public provider, Ley 9234’s institutional-authorization requirement is a real gate. The CCSS biomedical-research reglamento sits on CONIS’s legislation list for a reason. Private sites still need the legal representative of the institution to authorize the study — Resolución-style “IRB only” thinking is incomplete. Then SIV, device accountability, EDC, and the first screening visit.

    Weeks 14–20 — FPI. First procedure only after CEC written approval, CONIS registration (and canon), institutional authorization, and release of investigational units. If any one of those four is missing, you do not have an activation date. You have a slide.

    What actually belongs in the CEC package

    Decreto 39061-S Article 44 is the index, not your U.S. IDE table of contents. In practice a device FIH package that survives first review contains:

    • Spanish protocol with a Costa Rican PI who can defend first-human risk, stopping rules, and follow-up.
    • Investigator brochure and IFU that define expected adverse device effects in the same language the consent uses.
    • Informed consent that a CONIS-accredited CEC can read as Ley 9234-compliant, not a translated U.S. IRB form with the letterhead swapped.
    • Insurance that names the Costa Rican site and participants, not only the Delaware sponsor.
    • Device identification (model, lot/serial logic, sterility, remaining risks) consistent with ISO 14155 investigational labeling.
    • Signed budget / contract copy the CEC can forward to CONIS for the canon calculation.
    • Evidence the chosen CEC is CONIS-accredited — or a written path to the Ministry of Health CEC for Phase I.

    CONIS’s international list includes ICH E6. That does not mean a drug monitoring plan is enough for an implant. If you later want FDA to look at the file under 21 CFR 812.28, the study must be scientifically valid, conducted under GCP, and inspectable. Build source documents and device accountability as if an FDA investigator will ask for them. Costa Rica’s law does not forbid that discipline. Sloppy EDC does.

    What slips FPI after “ethics is approved”

    Three failures repeat. First, the sponsor pays the 3% canon on a draft budget and then amends the contract up; CONIS has a different number than the CEC. Second, the site is public and nobody owned the institutional letter. Third, investigational units arrive with commercial labeling or a quantity that does not match the registered protocol. None of those are CONIS “delays.” They are activation defects.

    A fourth defect is quieter: treating Costa Rica as a one-country shop and then changing the intended purpose so the same device can be registered later under RTCR 505:2022. Registration and FIH are different files. If the indication you implant is not the indication you will later put on a Costa Rica Registration Holder dossier, say so now. Do not let the activation calendar inherit a commercial story you have not written.

    A one-page gate before you book travel

    Write eight lines with an owner and a document ID. Do not announce FPI week until each line is true.

    1. Intended purpose in Spanish that will appear in the protocol, brochure, and consent.
    2. Phase I / first-in-human call: Ministry of Health CEC versus a named CONIS-accredited site CEC, in writing.
    3. Complete Article 44 package, in Spanish, with insurance and budget attached.
    4. CEC written approval (and query closure).
    5. Institutional authorization if the site is public or otherwise requires it under Ley 9234.
    6. CONIS registration of the approved project.
    7. 3% canon paid on the same budget the CEC forwarded.
    8. Investigational units released against the registered protocol, labeled as investigational.

    If those eight lines cannot be signed in one sitting, you do not have a Costa Rica activation calendar. You have a hope that “LATAM is faster.” The statute is faster than a U.S. IDE when the file is complete. It is not faster than a missing CEC letter.

  • Adverse event and SUSAR reporting to ANVISA during a FIH trial in Brazil

    Device FIH safety reporting in Brazil is not drug pharmacovigilance with the logo swapped. The clocks are different, the form is different, and “SUSAR” is a useful overlapping idea — not the name of the ANVISA device channel.

    If your FIH data are meant to support a later FDA investigational or marketing file, you still report to ANVISA under device rules. You then keep a narrative and causality trail that an IDE medical officer can read without asking why Brazil used a drug module.

    The statute you actually report under

    Current device clinical-investigation procedure is RDC 837/2023, announced by ANVISA in its December 2023 update. It replaced RDC 548/2021, which had already revoked RDC 10/2015. Chapter VII is the safety-monitoring chapter. Do not write SOPs against RDC 10/2015 clocks, and do not paste RDC 945/2024 drug-trial SUSAR text into a device FIH plan.

    Law 14.874/2024 still applies to the ethics layer. Article 26 requires the sponsor to notify investigators, the institution, ethics bodies, and the sanitary authority of findings that may adversely affect participant safety. Article 55 makes serious adverse events reportable to the CEP that approved the research, and, for clinical trials intended to support sanitary registration, also to the sanitary authority. The law does not replace RDC 837/2023’s device form or day counts.

    NotivisaEC is the device channel; VigiMed is not

    ANVISA’s manual for adverse-event notification and safety monitoring in clinical trials involving investigational medical devices is the operational text. It tells sponsors to notify unexpected serious adverse events to ANVISA on the electronic NotivisaEC form:

    https://pesquisa.anvisa.gov.br/index.php/847543?lang=pt-BR

    The manual is explicit that those notifications go exclusively through that form, and that login is not required to notify. It also states that a SUSAR (suspected unexpected serious adverse reaction) sits inside the criteria for a notifiable serious event — but the RDC criteria are not limited to the drug-style SUSAR definition. If your safety database only flags “SUSAR = yes,” you will miss device cases that are unexpected, serious, and causally possible even when a medical monitor refuses the drug label.

    VigiMed-Pesquisa Clínica is ANVISA’s channel for SUSARs in drug and biologic trials, under the drug clinical-trial framework (currently discussed by the Agency against RDC 945/2024). ANVISA’s own clinical-trial notification page describes VigiMed in that medicine context and requires a study-specific VigiMed registration, including the DEEC expediente. That is not the device DICD file. Do not open a VigiMed-Pesquisa Clínica account as a substitute for NotivisaEC on an implant FIH.

    Post-market technovigilance (commercial devices after registro or notification) is a different duty and a different system generation. Keep investigational NotivisaEC cases out of the commercial technovigilance queue until the unit is actually on the market.

    What is notifiable, in device language

    RDC 837/2023 defines an adverse event as any unfavorable medical occurrence in a participant that is not necessarily causal. A serious adverse event includes death; a life-threatening event; persistent or significant disability; hospitalization or prolongation of hospitalization; congenital anomaly; suspected transmission of an infectious agent via a medical device; or a clinically significant event.

    An event is unexpected when it is not described as an adverse reaction in the investigator brochure or in the instructions for use / operator manual of the investigational device. That is why the brochure is a reporting instrument, not a marketing appendix.

    The sponsor must notify ANVISA of unexpected serious events that occurred in Brazil and whose causality versus the investigational product is possible, probable, or definite. Expected serious events, unrelated events, and non-serious events still belong in the sponsor’s file and in the annual tabulated report. They are not the 7- and 15-day electronic cases.

    Causality is not a hallway opinion. The device manual points sponsors to the WHO-UMC causality scale (possible / probable / certain, plus the lower categories) when classifying every event, including non-serious ones. Train Brazilian investigators on that scale before site initiation. A PI who only knows “related / not related” will force you to re-code under the clock.

    The clocks — investigator, sponsor, ANVISA

    RDC 837/2023 is blunt on time. Count from knowledge, not from “when safety closed the query.”

    • Investigator → sponsor: serious adverse events or death within 24 hours of the investigator becoming aware.
    • Sponsor → ANVISA, fatal or life-threatening, unexpected, causality possible/probable/definite, Brazil: document and notify on the electronic form within 7 calendar days of sponsor awareness. Complementary follow-up goes on the same form within 8 calendar days after that initial notification.
    • Sponsor → ANVISA, all other unexpected serious events meeting the same causality and territory tests: 15 calendar days from sponsor awareness.

    Immediate protective measures are not optional. On a notifiable serious event, the form expects the measures already taken, the plan if the same event recurs, the care location, and identifiers that can trace the event and the participant. Notification is due even if you are in the middle of a brochure update, a protocol amendment, an annual report, or an early termination.

    Temporary safety suspensions of the investigation must be notified to ANVISA within 7 calendar days of the suspension, with reasons, scope, treatment interruption, risk-minimization measures, and recruitment status. Restart waits for ANVISA approval published in the Official Gazette. That is a calendar item, not a medical-monitor footnote.

    DSUR / ICH E2F is not a substitute for the device annual report

    ANVISA publishes the ICH E2F Development Safety Update Report in its medicines clinical-trial library. E2F is a drug-development periodic-safety standard. It is a sensible internal template if the same legal entity also runs an IND. It is not the device annual report that RDC 837/2023 requires.

    For a DICD, the sponsor files an annual follow-up report as a secondary petition to the DICD, covering Brazilian centers only, in tabulated form: title, reference number, recruitment status, amendment history, enrollment by site, deviations and violations by site, and a description of all adverse events in the period, with the case-report-form participant codes. The anniversary is the date of the Brazil start-of-investigation notification. The petition is due within 60 calendar days of that anniversary. Missing the report can cancel the investigation.

    The final report is a different secondary petition, due within 12 months of the investigation’s end date, with demographics, statistical analysis, all events with causality, endpoint results, and any design changes. If you already produce a DSUR for a companion drug or combination product, map the Brazilian device tables into an annex. Do not file the DSUR and assume ANVISA has been served.

    Pivotal high-risk (Class III/IV) designs are expected to constitute a data-monitoring committee. Recommendations go to ANVISA as a DICD addendum within 30 calendar days of the sponsor receiving them. An FIH that is not labeled “pivotal” can still justify a DMC on risk. Write that justification in the plan before first patient, including why you did not constitute one.

    What must stay aligned if the FIH will later support FDA

    FDA device investigations do not use the IND SUSAR clock. They use unanticipated adverse device effect (UADE) rules under 21 CFR 812.150. An investigator reports a UADE to the sponsor and reviewing IRB as soon as possible, and no later than 10 working days after first learning of it. The sponsor evaluates immediately and reports the evaluation to FDA, all reviewing IRBs, and participating investigators within 10 working days of first notice. If the UADE presents an unreasonable risk, termination clocks in 21 CFR 812.46 are 5 working days from that determination and 15 working days from first notice. FDA’s IDE FAQs repeat the same 10-working-day sponsor evaluation report.

    Those clocks will not match Brazil’s 24-hour / 7-calendar / 15-calendar structure. Alignment is not “pick the longer one and hope.” Alignment is a single source narrative:

    • One event identifier from the Brazilian CRF code through NotivisaEC and, if an IDE exists or will exist, through the UADE file.
    • One expectedness baseline — the same brochure version cited in the DICD and in the IDE investigational plan. If Brazil updates the brochure after an unexpected event (RDC 837/2023 requires investigators to be informed and the brochure to be updated), send that version into the FDA file in the same week.
    • One causality sentence that a device reviewer recognizes (device, procedure, disease, concomitant product). Do not let the Brazilian form say “possible” and the IDE memo say “unrelated” without a dated reconciliation.
    • Device identifiers — lot, serial, software version, accessory — on every case. Import traceability under the DICD DOU number is the same data FDA will ask for when the unit later supports a 510(k), De Novo, or PMA.
    • Quality-system evidence that the investigational unit was built under a system you can defend as you move toward the QMSR. A NotivisaEC case that cannot find the device history record is already a future FDA inspection finding.

    If there is no U.S. IDE yet, still write Brazilian cases as if 812.150 will apply later. Reconstructing UADEs from a drug-safety database two years on is how FIH datasets lose credibility.

    Where programs actually break

    The bottleneck is rarely the web form. It is the weekend between the PI’s 24-hour email and a U.S. medical monitor who is still arguing expectedness against an old brochure. Build a Brazil on-call roster that can file NotivisaEC without waiting for California business hours. Give the Brazilian authorized representative and the ORPC (if one is the DICD face) read-only access to the safety tracker. Import holds, ethics queries, and ANVISA inspections all ask for the same case list.

    Second break: treating CEP notification and ANVISA notification as the same send. Law 14.874/2024 sends serious events to the CEP. RDC 837/2023 sends a narrower unexpected-and-related set to ANVISA on NotivisaEC. Your SOP should have two lines, two clocks, two receipts.

    Third break: annual-report amnesia. The 60-day secondary petition is how ANVISA sees aggregate harm. If your data-management lock cannot produce site-level AE tables from Brazilian CRF codes, you will miss a petition that can cancel the DICD — after first patients are already in.

    A practical next step

    Before site initiation, run one tabletop: a fatal unexpected device-related event at 18:00 Brasília on a Friday. Walk the 24-hour investigator notice, the 7-calendar-day NotivisaEC filing, the 8-day follow-up, the CEP notice under Law 14.874/2024, the brochure update, and — if an IDE is live or planned — the 10-working-day UADE evaluation to FDA. If any of those hands is “we’ll figure it out,” rewrite the safety SOP and name the NotivisaEC filer. First-patient week is the wrong time to discover that VigiMed was the only account anyone opened.

  • ANVISA medical device classification rules for FIH studies in Brazil

    Most first-in-human (FIH) delays I see in Brazil do not start on the ANVISA clock. They start earlier, when regulatory affairs treats class as a registration afterthought instead of the decision that decides whether you even file a clinical investigation dossier, what the import petition can carry, and what the investigator brochure must treat as expected.

    This is not another walkthrough of Brazil’s 90-day ANVISA review window, and it is not a recap of Law 14.874/2024. Those calendars matter, but they sit on top of a classification call. If that call is wrong, the clock you are watching is the wrong clock.

    RDC 751/2022 is the class rule, not a slogan

    Collegiate Board Resolution RDC No. 751 of 15 September 2022 is ANVISA’s current framework for medical-device risk classification, labeling and instructions for use, and the notification versus marketing-authorization (registro) regimes. Article 5 places devices in four intrinsic-risk classes:

    • Class I — low risk
    • Class II — medium risk
    • Class III — high risk
    • Class IV — maximum risk

    Articles 6 and 7 then split the premarket path: Classes I and II are subject to notification; Classes III and IV are subject to marketing authorization. ANVISA’s English overview of the same split is on the Agency’s medical devices page.

    Classification is not a marketing preference. It is a rules exercise against the manufacturer’s intended purpose. Annex I of RDC 751/2022 sets the classification rules (duration of use, invasiveness, active energy, implants, special rules). The most stringent applicable rule wins. Software as a medical device is classified on its own intended purpose when it is standalone. In vitro diagnostic devices sit on a separate IVD classification track; do not force an IVD into the same clinical-investigation box as an implant.

    For an FIH program, lock three statements in the same document: intended purpose in Portuguese that will appear on the DICD and later on the registro file; the Annex I rule (or rules) you applied; and the resulting Class I–IV. If clinical, quality, and the Brazilian authorized representative cannot repeat those three lines without hedging, you are not ready to talk about first-patient dates.

    RDC 10/2015 is not the current FIH filing rule

    Sponsors still arrive with “RDC 10/2015” in the regulatory plan. That resolution existed. It is not the current device-investigation statute.

    RDC No. 548 of 30 August 2021 revoked RDC No. 10 of 20 February 2015 (Article 84 of RDC 548/2021). RDC No. 837 of 13 December 2023 then replaced that 2021 text. ANVISA announced the update and the alignment with international practice in its 18 December 2023 notice (in force early January 2024). Article 80 of RDC 837/2023 revokes RDC 548/2021.

    Current device clinical-investigation procedure is RDC 837/2023. Use RDC 10/2015 only as history. Do not cite it as the filing basis for a 2026 FIH.

    How class drives whether you file a DICD

    RDC 837/2023 is explicit about scope. A Dossiê de Investigação Clínica de Dispositivo Médico (DICD) is required for clinical investigations involving Class III or Class IV devices that are not yet registered in Brazil. A registered device studied for an indication different from the indication in the sanitary registration also goes in as a DICD.

    The same resolution carves out investigations that do not go to ANVISA as a DICD, including:

    • clinical performance studies of IVDs;
    • usability/human-factors-only studies (unless the clinical investigation also includes those endpoints among others);
    • investigations of devices already registered in Brazil for the same approved indications;
    • clinical investigations of Class I or Class II devices.

    Class I and II investigations are still expected to follow good clinical practice. RDC 837/2023 points to the Document of the Americas and ISO 14155 as the GCP standard. They still need ethics approval. They do not get a free pass on import controls or on manufacturing quality of investigational units. What they do not get is a DICD as the ANVISA on-ramp.

    That is the classification bottleneck. A U.S. significant-risk implant that an RA lead quietly “simplifies” to Class II to avoid a dossier is not a timeline win. It is a first-patient hold when import, ethics, or a later registro reviewer asks why the intended purpose looks like Rule 8 (long-term surgically invasive / implant) and the file says Class II. The opposite error is also expensive: forcing a true Class II tool through a DICD because someone copied a Class III playbook wastes petition fees and a review cycle you did not owe.

    What the DICD actually has to carry

    When class puts you in DICD scope, RDC 837/2023 consolidates the old two-dossier habit into one submission. The petition typically includes the DICD form, the sanitary-surveillance fee (GRU) or exemption, the investigator brochure, a safety-experience summary (prior human use and any foreign post-market experience), the investigational-device dossier, the clinical investigation plan under GCP, and proof of registration in a WHO ICTRP or ICMJE-recognized trial registry (or that proof at start-date notification if it is not ready at first protocolization).

    ANVISA’s petition checklist for DICD subject 80104 is published in the Agency’s SAT instruction list. Use that list, not a recycled IND table of contents.

    Two operational rules from the same resolution save weeks if you lock them before translators start:

    • The party who files the DICD owns every later secondary petition. Do not let a consultant file “just this once.”
    • An organização representativa de pesquisa clínica (ORPC) may file only when the sponsor has no headquarters or branch in Brazil. If you already have a Brazilian legal presence, that presence is the face of the file.

    RDC 837/2023 gives ANVISA 90 calendar days (dias corridos) to issue a manifestation on the DICD, with a tacit-start path after ethics approval if the Agency is silent. Law 14.874/2024 Article 58 speaks of 90 business days (dias úteis) for primary sanitary analysis of clinical-trial petitions intended to support registration. Those are not the same unit of time. Treat the mismatch as a planning flag; do not invent a hierarchy in a slide. The clock posts already cover activation math. Classification decides whether that math applies to you at all.

    Import, IOR/AR, and QMSR sit on the same class decision

    Investigational units do not enter Brazil on a commercial registro. RDC 837/2023 Chapter IX puts exclusive clinical-use import under sanitary inspection and SISCOMEX release. The importer must cite the Diário Oficial da União resolution number for the DICD grant. Outer packaging must carry that DOU number, storage conditions, and a lot, identification, or serial code that can trace the unit. Quantities are limited to what the investigation needs. Commercialization of those units is prohibited.

    If someone other than the DICD holder imports, both parties sign a delegation-of-import-responsibility document. That is your import authorized representative problem, not a freight problem. The same legal person who will later hold notification or registro as authorized representative should see the investigational import list now. A first-patient kit that is not on the DICD product list will sit on the dock.

    On quality: RDC 837/2023 requires investigational devices, and any placebo or sham, to be manufactured to good manufacturing practice and labeled so they are identifiable as investigational. ANVISA may inspect the manufacturing site against the technical, production, and quality-control story in the DICD. If the same design will later support an FDA marketing file, build those units under the quality system you intend to defend — including the United States Quality Management System Regulation transition — not under a “prototype exception” that you cannot reconstruct.

    What the RA lead must lock before first patient

    Write these eight items as a one-page gate. Do not open the site until each line has an owner and a document ID.

    1. Intended purpose. The Portuguese indication that will classify the device under RDC 751/2022 Annex I and that will appear in the investigator brochure. Changing “long-term implant” to “intraoperative aid” after ethics approval is a new class, not a wording tweak.
    2. Class and rule. Class I–IV plus the governing Annex I rule. Record why neighboring rules were rejected.
    3. DICD yes/no. Apply RDC 837/2023 Articles 2 and 4. Class I/II, same-indication post-market, IVD performance, and usability-only studies are out of DICD scope. Class III/IV unregistered, and new indications on a registered device, are in.
    4. Filing face. Sponsor legal entity in Brazil versus ORPC. Name the person who will own secondary petitions: start/end dates, amendments, annual report.
    5. Import list. Every investigational SKU, spare, and accessory that will clear SISCOMEX, mapped to the DICD form. No “we’ll add the introducer later.”
    6. Expectedness language. The brochure and operator manual define “unexpected” for later safety notification. If the FIH protocol lists risks the brochure omits, you have built a 7- and 15-day reporting trap.
    7. Ethics path. CEP submission under Law 14.874/2024 in parallel with, not after, the sanitary file when a DICD is in scope. Single-CEP review for multicenter protocols is a legal design, not a courtesy.
    8. Start-date discipline. RDC 837/2023 requires start- and end-date forms as secondary petitions within 30 calendar days of each Brazil date. First patient is a regulatory event, not only a clinical one.

    Amendments after that gate are expensive. Substantial changes to the brochure or device dossier that can affect quality or safety wait for ANVISA manifestation (again, 90 calendar days in RDC 837/2023). Substantial protocol amendments that affect participant safety or scientific value wait the same way, except amendments that remove an immediate risk, which you implement and notify. Classification mistakes tend to surface as those amendments.

    A practical next step

    This week, run a 90-minute classification huddle with RA, clinical, quality, and the Brazilian representative. Put the intended-purpose sentence, the Annex I rule, the Class I–IV result, and a yes/no DICD decision on one page. Attach the RDC 751/2022 English text and the RDC 837/2023 scope articles. If those four people cannot sign the page, do not book first-patient week. The calendar you save is not ANVISA’s — it is the month you would have spent unscrewing a class you never locked.

  • 4 Key Strategies for Phase 1 Clinical Trials in El Salvador

    4 Key Strategies for Phase 1 Clinical Trials in El Salvador

    Introduction

    El Salvador is rapidly becoming a key player in phase 1 clinical trials, but can sponsors truly harness its potential? This Central American nation offers a unique blend of rapid regulatory approvals and cost efficiencies that can significantly benefit MedTech and Biopharma startups.

    • With approval timelines averaging just 30 to 60 days
    • Per-patient costs ranging from $15,000 to $35,000 – substantially lower than US and EU benchmarks

    El Salvador offers a compelling opportunity for early-stage clinical research. But how can sponsors tackle the local regulatory landscape and boost their patient recruitment strategies to get the best results?

    Understand the Regulatory Landscape for Phase 1 Trials in El Salvador

    Navigating the regulatory landscape for phase 1 clinical trial El Salvador presents both opportunities and challenges for sponsors. The authorization procedure is impressively swift, typically taking just 30 to 60 days. This positions El Salvador as one of the fastest options in Latin America for launching phase 1 clinical trial El Salvador. Adherence to ICH-GCP guidelines is essential for all studies, ensuring compliance with international standards. Sponsors must effectively navigate the submission pathways, utilizing the SRS-CNEIS-ES platform for electronic submissions, which streamlines the process.

    Understanding the ethical review requirements, which usually take around 30 days, is crucial for a smooth start and execution of your study. Conducting studies in El Salvador also provides notable cost efficiency, with per-patient expenses ranging from $15,000 to $35,000, significantly lower than the $40,000 to $75,000 range in the US and EU.

    How can startups leverage bioaccess®’s Global Trial Accelerators™ to navigate this landscape effectively and boost their chances of successful trial outcomes? Notably, bioaccess® guarantees a 12-month protocol-to-last-patient-last-visit timeline, ensuring expedited processes.

    Furthermore, our partnership with Greenlight Guru enhances our capabilities with cloud-based quality management system (QMS) and clinical electronic data capture (EDC) integration, providing additional value to our clients. By embracing these insights and strategies, sponsors can significantly enhance their chances of achieving successful trial outcomes in a competitive landscape.

    This flowchart shows the steps involved in launching a phase 1 clinical trial in El Salvador. Each box represents a key stage in the process, and the arrows guide you through the sequence from start to finish. If you reach the decision box and need to revise your submission, you can loop back to the submission pathways.

    Prepare Essential Documentation and Compliance Requirements

    Initiating a phase 1 clinical trial El Salvador presents unique challenges that require meticulous preparation. Sponsors must prepare several key documents, including:

    1. Clinical Trial Protocol
    2. Investigator’s Brochure
    3. Informed Consent Forms

    Are your documents ready? They must be in Spanish and comply with local regulations to ensure a smooth approval process. Ethical approvals from an Institutional Review Board (IRB) or Ethics Committee are mandatory, typically taking around 30 days for review.

    The SRS-CNEIS-ES platform can streamline submissions significantly. This enhances communication with regulatory authorities and allows for real-time tracking of approval status. Additionally, sponsors should include comprehensive safety data and product information to support their applications. Thorough preparation can lead to quicker approvals, allowing sponsors to launch their studies sooner, typically within 30 to 60 days. Engaging local compliance consultants can provide valuable insights into the Salvadoran regulatory landscape, further ensuring adherence to ICH-GCP standards and local requirements.

    With bioaccess®’s expertise, sponsors can anticipate commencing phase 1 clinical trial El Salvador studies within 6-8 weeks and providing FDA-bridgeable data roughly 40% quicker than US/EU pathways, significantly enhancing their chances of a successful trial launch. By leveraging local expertise and streamlined processes, sponsors can significantly enhance their chances of a successful trial launch.

    This flowchart outlines the steps needed to prepare for a phase 1 clinical trial in El Salvador. Each box represents a key action or document required, and the arrows show the order in which these steps should be completed. Following this process can help ensure a smooth approval and launch of the trial.

    Implement Effective Patient Recruitment Strategies

    Recruiting patients for the phase 1 clinical trial in El Salvador requires a strategic approach that prioritizes local engagement and logistical considerations. Sponsors should focus on leveraging local networks and collaborating with healthcare providers to identify potential participants. Getting the community involved is key. Hosting informational sessions and using social media can really boost awareness about the study. Additionally, offering incentives for participation can further enhance recruitment rates.

    It’s essential to consider the diverse demographics of El Salvador, tailoring recruitment strategies to address cultural sensitivities and preferences. This distance creates significant barriers to participation, complicating recruitment efforts, especially since 70% of potential clinical study participants reside more than two hours from a research center. Therefore, logistical factors such as home visits can be especially advantageous.

    Additionally, it is crucial to adhere to local regulatory bodies like INVIMA and comply with ICH-GCP guidelines to ensure the study’s success. By implementing these targeted strategies, sponsors can achieve higher enrollment rates and accelerate the completion of their studies.

    Collaborating with bioaccess® can further enhance this approach, as they offer vital clinical insights and market access strategies customized for MedTech and Biopharma firms in Latin America. Their expertise in navigating regulatory challenges and their established local networks can significantly enhance recruitment efforts, ensuring a more efficient study process. Successful partnerships with clients such as Mitralign and ClarVista Medical showcase bioaccess®’s ability to facilitate effective patient recruitment and study execution.

    By embracing these strategies, sponsors can not only enhance recruitment but also ensure the timely advancement of their clinical studies.

    This flowchart outlines the steps to effectively recruit patients for clinical trials. Each box represents a strategy or action, and the arrows show how these strategies connect and lead to successful recruitment.

    Leverage Technology for Efficient Trial Management

    In the fast-paced world of clinical research, the efficiency of phase 1 clinical trial El Salvador hinges on the strategic use of Clinical Trial Management Systems (CTMS). These systems enable real-time tracking of patient enrollment, site management, and adherence to regulatory compliance, a critical factor in adhering to the stringent standards established by local authorities like INVIMA and ICH-GCP.

    Furthermore, electronic information capture (EIC) systems enhance the collection of information, reducing the likelihood of mistakes linked to manual entry. The integration of remote monitoring technologies allows for effective oversight of patient safety and study progress without necessitating frequent site visits.

    Embracing these technological solutions empowers sponsors to boost operational efficiency, safeguard information integrity, and accelerate the timeline from protocol approval to study completion. A standout example is bioaccess®, which has pioneered the Innovation Runway, accelerating clinical development pathways for MedTech, Biopharma, and Radiopharma startups, enabling them to reach clinical milestones 40% faster.

    This is especially beneficial in Latin America, where the capability to initiate first-in-human studies within 6-8 weeks and provide FDA-bridgeable findings roughly 40% quicker than US/EU routes can greatly improve the research process. For instance, the electronic data capture systems market is projected to grow significantly, reaching USD 7.4 billion by 2036, indicating a robust demand for such technologies.

    Moreover, case studies from successful clients like Mitralign and enVVeno Medical illustrate that implementing CTMS can reduce study timelines by up to 30%, offering a compelling reason for sponsors to adopt these systems. For successful CTMS implementation, sponsors must prioritize team training and ensure compliance with all regulatory requirements to facilitate a smoother path to regulatory approval and market access.

    Ultimately, the right technological investments can redefine the landscape of clinical trials, paving the way for groundbreaking advancements in healthcare.

    This flowchart illustrates how different technologies contribute to efficient clinical trial management. Each box represents a technology or benefit, and the arrows show how they connect to improve the overall process.

    Conclusion

    El Salvador is not just another location for phase 1 clinical trials; it’s a strategic hub that can redefine your research outcomes. This region offers a unique blend of rapid regulatory approvals, cost efficiency, and effective patient recruitment strategies. Sponsors who harness the advantages of this region will dramatically improve their chances of achieving successful trial outcomes, even amidst the complexities of early-stage clinical research.

    Key strategies discussed include:

    1. Understanding the regulatory landscape
    2. Preparing essential documentation
    3. Implementing effective patient recruitment methods
    4. Utilizing advanced technology for trial management

    The swift approval timelines of 30 to 60 days, coupled with cost savings of approximately 30% per patient compared to US and EU benchmarks, make El Salvador an attractive option for MedTech and Biopharma companies. Additionally, the ability to initiate trials within 6-8 weeks and deliver FDA-bridgeable data approximately 40% faster than traditional pathways further underscores the region’s potential.

    Embracing these strategies is not just about streamlining the clinical trial process; it’s about seizing the unique opportunities that El Salvador offers. By partnering with specialized organizations like bioaccess®, companies can navigate the regulatory landscape effectively, enhance patient recruitment efforts, and leverage technology to ensure efficient trial management. In a landscape where timing and efficiency are paramount, the right partnerships can make all the difference in achieving clinical success.

    Frequently Asked Questions

    What is the typical timeline for obtaining authorization for phase 1 clinical trials in El Salvador?

    The authorization procedure for phase 1 clinical trials in El Salvador typically takes just 30 to 60 days, making it one of the fastest options in Latin America.

    What guidelines must sponsors adhere to when conducting studies in El Salvador?

    Sponsors must adhere to ICH-GCP guidelines, which ensure compliance with international standards for clinical trials.

    How can sponsors submit their trial applications in El Salvador?

    Sponsors can utilize the SRS-CNEIS-ES platform for electronic submissions, which streamlines the submission process for clinical trials.

    What is the duration of the ethical review process for clinical trials in El Salvador?

    The ethical review process usually takes around 30 days, which is crucial for a smooth start and execution of the study.

    What are the cost implications of conducting clinical trials in El Salvador compared to the US and EU?

    Conducting studies in El Salvador offers notable cost efficiency, with per-patient expenses ranging from $15,000 to $35,000, significantly lower than the $40,000 to $75,000 range in the US and EU.

    How can startups benefit from bioaccess®’s Global Trial Accelerators™?

    Startups can leverage bioaccess®’s Global Trial Accelerators™ to effectively navigate the regulatory landscape and boost their chances of successful trial outcomes.

    What timeline guarantee does bioaccess® provide for phase 1 trials?

    bioaccess® guarantees a 12-month protocol-to-last-patient-last-visit timeline, ensuring expedited processes for phase 1 trials.

    How does bioaccess® enhance its capabilities for clinical trials?

    bioaccess® enhances its capabilities through a partnership with Greenlight Guru, which provides cloud-based quality management system (QMS) and clinical electronic data capture (EDC) integration.

    List of Sources

    1. Understand the Regulatory Landscape for Phase 1 Trials in El Salvador
      • 9 Affordable Clinical Trial Options in El Salvador for Startups | bioaccess® (https://bioaccessla.com/blog/9-affordable-clinical-trial-options-in-el-salvador-for-startups)
      • Achieve Fast Clinical Trial Approval in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/achieve-fast-clinical-trial-approval-in-el-salvador-a-step-by-step-guide)
      • 4 Steps to Secure Clinical Trial Approval in El Salvador | bioaccess® (https://bioaccessla.com/blog/4-steps-to-secure-clinical-trial-approval-in-el-salvador)
      • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
    2. Prepare Essential Documentation and Compliance Requirements
      • Achieve Fast Clinical Trial Approval in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/achieve-fast-clinical-trial-approval-in-el-salvador-a-step-by-step-guide)
      • How to Conduct a First-in-Human Clinical Trial in El Salvador | bioaccess® (https://bioaccessla.com/blog/how-to-conduct-a-first-in-human-clinical-trial-in-el-salvador)
      • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
    3. Implement Effective Patient Recruitment Strategies
      • Health Equity and Community Engagement – Velocity Clinical Research (https://velocityclinical.com/health-equity)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
    4. Leverage Technology for Efficient Trial Management
      • 12 Best Quotes on the Future of Healthcare (https://modmed.com/resources/blog/12-best-quotes-on-the-future-of-healthcare)
      • Electronic Data Capture Systems Market Size Report, 2030 (https://grandviewresearch.com/industry-analysis/electronic-data-capture-edc-systems-market)
      • Electronic Data Capture Systems Market Size & Forecast 2036 (https://factmr.com/report/electronic-data-capture-systems-market)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
      • Electronic Data Capture Systems Market Size to Hit USD 6.42 Bn by 2035 (https://precedenceresearch.com/electronic-data-capture-systems-market)

  • Best Practices for Early Phase Clinical Trials in El Salvador

    Best Practices for Early Phase Clinical Trials in El Salvador

    Introduction

    El Salvador stands at the forefront of early phase clinical trials, yet sponsors must navigate a complex landscape to fully harness its potential for MedTech and Biopharma startups. With a regulatory framework that allows for rapid approvals – often within 30 to 60 days – and significantly lower per-patient costs, the region offers a compelling opportunity for sponsors to accelerate their research timelines while upholding high compliance standards.

    Despite these advantages, sponsors face significant hurdles in understanding local regulations and effectively recruiting patients, necessitating strategic planning and innovative approaches. To overcome these challenges, sponsors must adopt innovative strategies that leverage El Salvador’s unique advantages to optimize their clinical trial outcomes and gain a competitive edge in drug development.

    Understand Early Phase Clinical Trials in El Salvador

    In the competitive landscape of drug development, early phase clinical studies, especially First-in-Human (FIH) investigations, play a pivotal role in ensuring safety and efficacy. In El Salvador, these assessments benefit from an efficient regulatory structure overseen by the Superintendencia de Regulación Sanitaria (SRS), enabling swift approvals usually within 30 to 60 days. This efficiency establishes El Salvador as a strategic hub for MedTech and Biopharma startups. Research costs here are about 30% lower than in the U.S. and EU, making research initiatives financially feasible, with expenses ranging from $15,000 to $35,000 per patient, compared to $40,000 to $75,000 in the U.S. and EU.

    The availability of proficient healthcare experts and an increasing interest in research among local communities further enhances the successful implementation of these studies. Engaging local healthcare providers not only boosts recruitment efforts but also builds trust within the community, which is crucial for keeping participants involved. Moreover, adherence to ICH-GCP standards guarantees high-quality data gathering, essential for preserving the integrity of research studies.

    Understanding these dynamics is vital for sponsors aiming to leverage El Salvador’s advantages in early phase research. By capitalizing on the region’s resources and expertise, companies can accelerate their development timelines and bring groundbreaking therapies to market more swiftly. The successful human implantation of SilkAxons™ by Newrotex underscores the potential for innovative advancements in the region. Embracing these opportunities not only enhances research outcomes but also positions sponsors at the forefront of medical innovation in the region.

    This mindmap starts with the central theme of early phase clinical trials and branches out into important areas that influence their success in El Salvador. Each branch represents a key factor, and the sub-branches provide more detailed insights. Follow the branches to understand how these elements connect and contribute to the overall landscape of clinical research in the region.

    Navigating the regulatory landscape in El Salvador can be daunting for sponsors, yet understanding it is crucial for successful clinical research. The Dirección Nacional de Medicamentos (DNM) oversees the regulatory framework for research studies, ensuring the safety and efficacy of proposed investigations. Sponsors must submit their clinical study applications through the SRS-CNEIS-ES platform, where meticulous preparation of all necessary documentation, including ethical approvals and study protocols, is essential.

    The review process typically spans 30 days, with ethical approvals averaging around the same timeframe. To speed up approvals, it’s vital for sponsors to submit thorough documentation that meets DNM standards. Adherence to ICH-GCP guidelines is crucial, guaranteeing that studies are conducted ethically and scientifically robust.

    By mastering these regulations, sponsors can significantly enhance their operational efficiency and reduce time to market. Conducting an early phase clinical trial in El Salvador for first-in-human studies not only accelerates the approval process but also offers substantial cost reductions, with per-patient expenses ranging from $15,000 to $35,000, compared to $40,000 to $75,000 in the US or EU.

    Moreover, with bioaccess®, sponsors can benefit from expedited Phase I first-in-human studies, securing ethics approvals in as few as 4-8 weeks and acquiring FDA/EMA-ready data, which greatly improves the efficiency of the process. This strategic edge establishes bioaccess® as a frontrunner in enabling early phase clinical trials in El Salvador and other early-phase studies in Latin America.

    This flowchart outlines the steps sponsors must take to navigate the regulatory landscape for clinical trials. Each box represents a key action in the process, and the arrows show how these actions connect. Following this flow will help ensure compliance and efficiency in conducting clinical research.

    Implement Effective Site Selection and Patient Recruitment Strategies

    Navigating the early phase clinical trial El Salvador landscape requires a strategic approach to site selection. To enhance site selection, sponsors should evaluate potential clinical research locations based on their historical performance, patient demographics, and infrastructure capabilities. Key strategies include:

    • Collaborate with Local Healthcare Providers: Enhancing site visibility and credibility is crucial for successful trial execution.
    • Employ Community Engagement Strategies: How can you utilize local networks, social media initiatives, and educational outreach to enhance awareness about the study? Tailoring recruitment messages to resonate with the local population can significantly boost enrollment rates.
    • Offer Incentives for Participation: Offering incentives can really encourage potential participants to get involved in the study, ensuring that recruitment goals are met efficiently.

    Did you know that, according to bioaccess®, regulatory approval timelines in the region average just 30 to 60 days, allowing studies to commence within an impressive 6-8 weeks? Moreover, carrying out medical studies in the region can lead to expenses between $15,000 and $35,000 per patient, considerably lower than the $40,000 to $75,000 generally observed in the U.S. and EU. By utilizing bioaccess®’s Innovation Runway, which guarantees a 12-month protocol-to-last-patient-last-visit timeline, companies can accelerate their development pathways, ensuring they reach critical funding milestones before their runway runs out. This distinctive route allows startups to reach first-in-human evaluations roughly 40% quicker than conventional U.S. and EU pathways, positioning Latin America, particularly El Salvador, as a strategic asset for early phase clinical trial El Salvador. By embracing these strategies, sponsors can not only enhance their trial outcomes but also contribute to the growth of the local healthcare ecosystem.

    This mindmap starts with the main goal at the center and branches out into key strategies. Each branch represents a different approach to enhancing clinical trial success, with further details on how to implement each strategy. Follow the branches to see how they connect and support the overall objective.

    Leverage Technology for Efficient Trial Management

    Incorporating technology into clinical trial management is essential for enhancing operational efficiency, especially in the early phase clinical trial El Salvador. Using electronic capture systems allows for real-time data collection and monitoring, significantly minimizing the risk of mistakes linked to manual entry. These systems streamline processes by ensuring that data is clean, complete, and compliant with regulatory standards such as ICH-GCP and local requirements from authorities like COFEPRIS.

    Remote monitoring tools further enhance oversight of study progress without the need for frequent site visits, conserving both time and resources. This capability is particularly advantageous in Latin America, where rapid patient recruitment can be achieved through technology-driven strategies. With bioaccess®, sponsors can leverage pre-qualified networks to achieve 50% faster enrollment, tapping into treatment-naïve patient populations.

    Moreover, implementing patient engagement platforms improves communication with participants, ensuring they stay informed and motivated throughout the study. By embracing these technological advancements, sponsors can streamline their processes and reduce costs. In fact, they can achieve approximately 30% lower per-patient costs compared to US/EU benchmarks. This also accelerates the timeline for bringing new therapies to market. The integration of EDC systems with management tools for studies ensures a unified oversight of operational and patient information, leading to enhanced study outcomes and adherence to regulatory pathways, including the capability to deliver FDA-bridgeable information approximately 40% faster than US/EU pathways. Furthermore, bioaccess® guarantees a 12-month protocol-to-last-patient-last-visit timeline, enhancing the efficiency of first-in-human trials. The partnership with Greenlight Guru for cloud-based quality management systems further strengthens the integration of clinical data capture and management. Ultimately, the integration of advanced technologies is not merely an option; it is a strategic imperative for sponsors aiming to lead in the competitive landscape of clinical research.

    This flowchart illustrates how different technologies contribute to efficient clinical trial management. Each branch represents a key area where technology plays a role, and the arrows show how these areas connect and support each other in improving trial outcomes.

    Conclusion

    In a landscape where clinical trial costs and timelines are under constant scrutiny, El Salvador emerges as a beacon of opportunity for early phase studies, particularly First-in-Human (FIH) trials. Its efficient regulatory framework and cost advantages make it an attractive option for MedTech and Biopharma startups. The streamlined approval process, typically completed within 30 to 60 days, allows sponsors to initiate trials swiftly. By leveraging the region’s resources, companies can cut research costs by about 30%. They can also significantly speed up their timelines.

    Key strategies for success in this landscape include:

    • Effective site selection
    • Community engagement
    • Integration of advanced technology

    Collaborating with local healthcare providers enhances recruitment efforts. Additionally, employing digital tools streamlines data management and monitoring. Sticking to ICH-GCP compliance means companies can collect high-quality data, which is essential for maintaining the integrity of clinical studies. Furthermore, the partnership with Greenlight Guru for cloud-based quality management systems exemplifies the innovative approaches that can be utilized to enhance trial efficiency.

    In summary, embracing the unique advantages of conducting early phase clinical trials in El Salvador positions sponsors for success and contributes to the growth of the local healthcare ecosystem. By capitalizing on the region’s regulatory efficiencies, cost savings, and technological advancements, companies can expedite their development pathways and bring groundbreaking therapies to market more effectively. Ignoring the potential of El Salvador could mean missing out on a pivotal opportunity to innovate and lead in clinical research.

    Frequently Asked Questions

    What is the role of early phase clinical trials in drug development?

    Early phase clinical trials, particularly First-in-Human (FIH) investigations, are crucial for ensuring the safety and efficacy of new drugs.

    How does the regulatory structure in El Salvador support early phase clinical trials?

    The regulatory structure in El Salvador, overseen by the Superintendencia de Regulación Sanitaria (SRS), allows for swift approvals of clinical trials, typically within 30 to 60 days.

    What are the cost advantages of conducting clinical trials in El Salvador?

    Research costs in El Salvador are approximately 30% lower than in the U.S. and EU, with expenses ranging from $15,000 to $35,000 per patient, compared to $40,000 to $75,000 in the U.S. and EU.

    How does local healthcare expertise impact clinical trials in El Salvador?

    The availability of proficient healthcare experts and growing interest in research among local communities enhance the successful implementation of clinical studies, improving patient recruitment and trust.

    What standards are adhered to in clinical trials conducted in El Salvador?

    Clinical trials in El Salvador adhere to ICH-GCP standards, ensuring high-quality data collection and maintaining the integrity of research studies.

    How can sponsors benefit from conducting early phase research in El Salvador?

    Sponsors can leverage El Salvador’s efficient regulatory environment, lower costs, and local expertise to accelerate development timelines and bring innovative therapies to market more quickly.

    Can you provide an example of a successful clinical trial in El Salvador?

    The successful human implantation of SilkAxons™ by Newrotex exemplifies the potential for innovative advancements in early phase clinical trials in the region.

    List of Sources

    1. Understand Early Phase Clinical Trials in El Salvador
      • Conduct FIH Clinical Trials in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/conduct-fih-clinical-trials-in-el-salvador-a-step-by-step-guide)
      • Navigate Clinical Trials: Choose the Right CRO in El Salvador | bioaccess® (https://bioaccessla.com/blog/navigate-clinical-trials-choose-the-right-cro-in-el-salvador)
      • Conducting clinical trials in El Salvador: ethical considerations and opportunities. | Julio G. Martinez-Clark posted on the topic | LinkedIn (https://linkedin.com/posts/juliomartinezclark_the-untapped-potential-of-clinical-trials-activity-7307430545007759361-jdhR)
      • 9 Affordable Clinical Trial Options in El Salvador for Startups | bioaccess® (https://bioaccessla.com/blog/9-affordable-clinical-trial-options-in-el-salvador-for-startups)
    2. Navigate Regulatory Requirements for Clinical Trials
      • Master Early Feasibility Study in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/master-early-feasibility-study-in-el-salvador-a-step-by-step-guide)
      • How to Conduct a First-in-Human Clinical Trial in El Salvador | bioaccess® (https://bioaccessla.com/blog/how-to-conduct-a-first-in-human-clinical-trial-in-el-salvador)
      • Achieve Fast Clinical Trial Approval in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/achieve-fast-clinical-trial-approval-in-el-salvador-a-step-by-step-guide)
      • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
    3. Implement Effective Site Selection and Patient Recruitment Strategies
      • Seven Best Practices For Clinical Trial Patient Recruitment (https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies)
      • 9 Affordable Clinical Trial Options in El Salvador for Startups | bioaccess® (https://bioaccessla.com/blog/9-affordable-clinical-trial-options-in-el-salvador-for-startups)
      • El Salvador: A hidden gem for clinical trials | Julio G. Martinez-Clark posted on the topic | LinkedIn (https://linkedin.com/posts/juliomartinezclark_the-untapped-potential-of-clinical-trials-activity-7303066787493957632-t7QU)
      • Five strategies we’ve learned in our 15 years to unlock clinical trial patient recruitment (https://innovativetrials.com/five-strategies-weve-learned-in-our-15-years-to-unlock-clinical-trial-patient-recruitment)
      • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
    4. Leverage Technology for Efficient Trial Management
      • Electronic Data Capture Systems for Clinical Trials and Research (https://egnyte.com/guides/life-sciences/electronic-data-capture)
      • 8 key benefits of electronic data capture for clinical trials | Viedoc (https://viedoc.com/blog/key-benefits-electronic-data-capture-clinical-trials)
      • Electronic Data Capture in Clinical Trials | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/electronic-data-capture-clinical-trials)
      • Remote Monitoring in Clinical Trials (https://obviohealth.com/resources/remote-monitoring-in-clinical-trials)
      • Benefits of Using an Electronic Data Capture (EDC) System in Clinical Trials (https://minervaresearchsolutions.com/blogs/electronic-data-capture-system-in-clinical-trials)

  • How to Conduct a First-in-Human Clinical Trial in El Salvador

    How to Conduct a First-in-Human Clinical Trial in El Salvador

    Introduction

    While El Salvador offers enticing benefits for clinical trials, the path to success is fraught with regulatory hurdles and recruitment challenges. This emerging destination for first-in-human clinical trials boasts rapid regulatory approvals and cost efficiencies that can significantly benefit MedTech, Biopharma, and Radiopharmaceutical companies.

    With an approval timeline of just 30 to 60 days and potential cost savings of 30% per patient compared to US and EU benchmarks, the region presents an attractive opportunity for early-stage research. However, navigating the regulatory landscape and implementing effective patient recruitment strategies can pose challenges.

    So, how can sponsors make the most of these advantages while staying compliant and achieving successful trial outcomes?

    Understand the Regulatory Landscape for FIH Trials in El Salvador

    Navigating the regulatory landscape is essential for the success of the first-in-human clinical trial in El Salvador. Understanding the regulatory environment is crucial, as the Superintendencia de Regulación Sanitaria (SRS) oversees research studies to ensure compliance with national health regulations. El Salvador, with an approval process that typically spans just 30 to 60 days, is an attractive location for conducting a first-in-human clinical trial in El Salvador.

    1. Familiarize Yourself with Key Regulations: Are you aware of the local laws governing clinical studies? Reviewing the Law on Duties and Rights of Patients and Healthcare Providers is essential, as it outlines the ethical considerations and rights of individuals involved.
    2. Engage with the DNM: The National Directorate of Medicines (DNM) evaluates the safety and efficacy of your proposed study design. Ensure that your study protocol aligns with their requirements to facilitate a smoother approval process.
    3. Prepare for Ethical Review: Before proceeding with your research, submit your study for ethical assessment to an Institutional Review Board (IRB) or Ethics Committee. This step is necessary to uphold ethical standards in clinical research.
    4. Understand ICH-GCP Compliance: Adhering to the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) guidelines is non-negotiable for ensuring data integrity and participant safety.
    5. Utilize the SRS-CNEIS-ES Platform: For electronic submissions, familiarize yourself with the SRS-CNEIS-ES platform, which streamlines the submission process and enhances communication with regulatory authorities.

    Understanding these regulatory nuances can significantly enhance your study’s success and efficiency in El Salvador.

    Each box represents a step you need to take to navigate the regulatory landscape for clinical trials. Follow the arrows to see the order in which these steps should be completed for a successful trial.

    Prepare Essential Documentation and Compliance Requirements

    Navigating the complex landscape of clinical study documentation can be daunting for researchers involved in the first-in-human clinical trial in El Salvador. Proper documentation is essential to the success of any clinical study, and here are the essential documents you need to prepare:

    1. Clinical Study Protocol: This document outlines the objectives, design, methodology, statistical considerations, and organization of the research. Ensure it meets the requirements set by the Superintendencia de Regulación Sanitaria (SRS) and the National Directorate of Medicines (DNM).
    2. Investigator’s Brochure: This comprehensive document provides information about the investigational product, including preclinical data, safety information, and dosing guidelines, which are crucial for ethical review.
    3. Informed Consent Documents: Create clear and concise informed consent documents that adhere to local regulations, ensuring that individuals comprehend the study’s purpose, procedures, risks, and benefits. These forms must be available in Spanish to facilitate comprehension.
    4. Ethics Approval Documentation: Obtain approval from an Institutional Review Board (IRB) or Ethics Committee, which is mandatory before commencing the study. This documentation should include ethical considerations and participant rights, typically taking 30 to 60 days for review. By leveraging bioaccess®, researchers can significantly reduce the time to initiate studies, enhancing efficiency and effectiveness.
    5. Safety Information and Product Details: Gather all pertinent safety information and product details to support the study’s safety profile. This includes any previous studies conducted on the investigational product, which must be documented thoroughly.
    6. Regulatory Submission Documents: Prepare all necessary documents for submission to the SRS, including the application form, study protocol, and any additional information requested by the regulatory authority. Utilizing the SRS-CNEIS-ES platform can streamline this process, enhancing communication and tracking of approval status.

    Furthermore, collaborating with local healthcare providers can greatly improve participant recruitment. Consistent audits and monitoring practices are essential for upholding compliance and ensuring the integrity of the study data. Conducting the first-in-human clinical trial in El Salvador can result in cost savings of about 30% lower per-patient expenses compared to the US or EU, making it an appealing choice for early-stage research. Embracing collaboration and innovative solutions like bioaccess® can transform your experience in the first-in-human clinical trial in El Salvador, paving the way for success.

    This flowchart outlines the key documents you need to prepare for a clinical trial. Each box represents a different document, and the arrows show the order in which you should tackle them. Following this path will help ensure you have everything in place for a successful study.

    Implement Effective Patient Recruitment Strategies

    Recruiting the right individuals for your first-in-human (FIH) study can be a daunting task, yet it is essential for success. Here are effective strategies to enhance patient recruitment in El Salvador:

    1. Leverage Local Networks: Collaborate with local healthcare providers and community organizations to raise awareness about the study. Building relationships with physicians facilitates referrals and enhances trust within the community.
    2. Utilize Digital Marketing: Implement targeted digital marketing campaigns to reach potential attendees. Use social media platforms and online health forums to share information about the study.
    3. Engage Patient Advocacy Groups: Collaborate with patient advocacy organizations that can assist in identifying and recruiting suitable candidates. These groups often have established trust within the community.
    4. Provide Incentives: Offer incentives for participation, including transportation assistance and compensation for time and travel, to drive enrollment.
    5. Conduct Community Outreach: Organize informational sessions in local communities to educate potential participants about the study’s purpose and benefits. This approach clarifies the research study process and promotes involvement.
    6. Monitor Recruitment Progress: Regularly assess recruitment metrics to identify challenges or barriers. Be prepared to modify strategies based on real-time feedback and information.

    By implementing these strategies, you can significantly enhance your recruitment efforts and ensure the success of your clinical research initiatives.

    Each box represents a strategy to recruit patients for clinical studies. Follow the arrows to see how each strategy leads to the next, helping you understand the overall approach to successful recruitment.

    Leverage Technology for Efficient Trial Management

    Integrating technology into the management of research studies is not just beneficial; it’s essential for enhancing efficiency and ensuring data integrity, especially in the first-in-human clinical trial in El Salvador. Utilizing the advantages of conducting studies in Latin America, such as accelerated regulatory approvals and cost reductions of around $25K per patient, can further strengthen your clinical research strategy. Here are essential technologies to consider:

    1. Electronic Information Capture (EIC): Implement EIC systems to streamline collection and management. These systems reduce entry mistakes and offer real-time access to study information, ensuring adherence to regulatory standards such as ICH-GCP. Significantly, clinical studies utilizing EDC systems can lower operational expenses by as much as 30%, making them a budget-friendly option for startups. With bioaccess®, you can achieve FDA-bridgeable results approximately 40% faster than US/EU pathways, and benefit from a 12-month protocol-to-last-patient-last-visit timeline guarantee.
    2. Remote Monitoring Tools: Utilize remote monitoring technologies to oversee study progress and subject safety without frequent site visits. This approach enhances data collection and involvement of individuals, crucial for maintaining high retention rates, especially in treatment-naïve patient populations.
    3. Telemedicine Solutions: Integrate telemedicine into your study design to facilitate virtual consultations and follow-ups, making it easier for participants to engage with the research while adhering to local regulations set by authorities like INVIMA.
    4. Clinical Trial Management Systems (CTMS): Utilize CTMS to oversee study logistics, including site management, patient tracking, and regulatory compliance. These systems ensure that all study aspects are organized and accessible, streamlining operations and supporting the rapid approval timelines of 4-8 weeks for the first-in-human clinical trial in El Salvador.
    5. Mobile Applications: Develop mobile apps for users to provide feedback, report adverse events, and access trial-related information. This can greatly improve engagement and retention of individuals, resulting in more precise results from the study.
    6. Data Analytics Tools: Utilize data analytics to track recruitment trends, participant demographics, and performance metrics of the study. This information can guide decision-making and enhance study outcomes, ensuring that your research meets its objectives efficiently.

    Without these technologies, clinical trials often face delays and increased costs, hindering research progress. By adopting these technologies, sponsors can enhance the efficiency of their clinical trials. This not only helps navigate the regulatory landscape more effectively but also leads to faster and more cost-efficient outcomes in the dynamic environment of Latin America. Ultimately, embracing these technologies is not merely an option; it’s a strategic imperative for sponsors aiming to thrive in the competitive landscape of clinical research in Latin America.

    This mindmap shows how different technologies can improve clinical trial management. Each branch represents a technology, and the sub-branches highlight their specific benefits. Follow the branches to see how each technology contributes to making trials more efficient and effective.

    Conclusion

    The potential for MedTech, Biopharma, and Radiopharmaceutical companies to conduct first-in-human clinical trials in El Salvador is not just an opportunity; it’s a strategic advantage waiting to be seized. With expedited regulatory pathways, cost efficiencies, and a robust patient recruitment landscape, El Salvador stands out as an ideal location for early-stage clinical research. Understanding the local regulatory framework and utilizing innovative technologies can help sponsors navigate the complexities of clinical trials effectively.

    Key insights from this guide emphasize the importance of:

    1. Familiarizing oneself with the regulatory landscape
    2. Preparing essential documentation
    3. Implementing effective patient recruitment strategies

    Engaging with local healthcare providers, utilizing digital marketing, and leveraging technology for trial management are crucial steps that can significantly enhance the success of first-in-human studies. Additionally, conducting trials in this region can save approximately 30% per patient compared to US and EU benchmarks, highlighting its financial viability.

    The landscape for first-in-human clinical trials in El Salvador is brimming with potential, and it’s time to take action. By embracing regulatory advantages, optimizing patient recruitment, and integrating advanced technologies, sponsors can not only expedite their research timelines but also achieve FDA-bridgeable data more efficiently. Stakeholders who act decisively in this promising landscape will not only enhance their research outcomes but also contribute to the future of healthcare innovation.

    Frequently Asked Questions

    What is the role of the Superintendencia de Regulación Sanitaria (SRS) in El Salvador regarding clinical trials?

    The SRS oversees research studies in El Salvador to ensure compliance with national health regulations, playing a crucial role in the approval process for clinical trials.

    How long does the approval process for first-in-human clinical trials typically take in El Salvador?

    The approval process in El Salvador typically spans just 30 to 60 days, making it an attractive location for conducting first-in-human clinical trials.

    What key regulations should be reviewed before conducting a clinical trial in El Salvador?

    It is essential to review the Law on Duties and Rights of Patients and Healthcare Providers, as it outlines the ethical considerations and rights of individuals involved in clinical studies.

    What is the function of the National Directorate of Medicines (DNM) in the clinical trial process?

    The DNM evaluates the safety and efficacy of the proposed study design, and it is important to ensure that the study protocol aligns with their requirements for a smoother approval process.

    What is required for ethical review before starting a clinical trial in El Salvador?

    Before proceeding with research, the study must be submitted for ethical assessment to an Institutional Review Board (IRB) or Ethics Committee to uphold ethical standards in clinical research.

    Why is compliance with ICH-GCP guidelines important in clinical trials?

    Adhering to the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) guidelines is essential for ensuring data integrity and participant safety during clinical trials.

    What is the SRS-CNEIS-ES platform, and how does it assist in the regulatory process?

    The SRS-CNEIS-ES platform is used for electronic submissions, streamlining the submission process and enhancing communication with regulatory authorities in El Salvador.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in El Salvador
      • Conduct a First-in-Human Study in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/conduct-a-first-in-human-study-in-el-salvador-a-step-by-step-guide)
      • 9 Affordable Clinical Trial Options in El Salvador for Startups | bioaccess® (https://bioaccessla.com/blog/9-affordable-clinical-trial-options-in-el-salvador-for-startups)
      • The Landscape Of Medtech Clinical Research In El Salvador | Julio G. Martinez-Clark (https://linkedin.com/posts/juliomartinezclark_the-landscape-of-medtech-clinical-research-activity-7297985823382142977-ChNJ)
      • Conducting clinical trials in El Salvador: ethical considerations and opportunities. | Julio G. Martinez-Clark posted on the topic | LinkedIn (https://linkedin.com/posts/juliomartinezclark_the-untapped-potential-of-clinical-trials-activity-7307430545007759361-jdhR)
      • Latin America the ‘Hidden Gem’ for First-in-Human Medical Device Trials (https://clinicalresearchnewsonline.com/news/2025/08/14/latin-america-the-hidden-gem-for-first-in-human-medical-device-trials)
    2. Prepare Essential Documentation and Compliance Requirements
      • User Guide for Clinical Trial Submissions on the SRS–CNEIS-ES Platform: El Salvador 2025 (https://regdesk.co/blog/user-guide-for-clinical-trial-submissions-on-the-srs-cneis-es-platform-el-salvador-2025)
      • Conduct FIH Clinical Trials in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/conduct-fih-clinical-trials-in-el-salvador-a-step-by-step-guide)
      • Conduct a First-in-Human Study in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/conduct-a-first-in-human-study-in-el-salvador-a-step-by-step-guide)
      • Conduct FDA Accepted Clinical Trials in El Salvador: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/conduct-fda-accepted-clinical-trials-in-el-salvador-a-step-by-step-guide)
      • Essential Documents in Clinical Trials (https://aceresearchafrica.com/mastering-essential-documents-in-clinical-trials-for-inspection-readiness)
    3. Implement Effective Patient Recruitment Strategies
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
    4. Leverage Technology for Efficient Trial Management
      • Benefits of Using an Electronic Data Capture (EDC) System in Clinical Trials (https://minervaresearchsolutions.com/blogs/electronic-data-capture-system-in-clinical-trials)
      • Electronic Data Capture In Clinical Trials | Credevo Articles (https://credevo.com/articles/2024/05/05/electronic-data-capture-in-clinical-trials-impact-advantages)
      • Benefits of Electronic Data Capture in Clinical Trials (https://clincapture.com/benefits-of-electronic-data-capture)
      • Clinical Trial Management System Market Statistics – 2034 (https://factmr.com/report/832/clinical-trial-management-systems-market)
      • How is AI Being Used in Clinical Trials? 5 Key Statistics for 2026 (https://medidata.com/en/life-science-resources/medidata-blog/how-is-ai-being-used-in-clinical-trials-5-key-statistics-for-2026)

  • Navigate Phase 1 Clinical Trials in Honduras: A Step-by-Step Guide

    Navigate Phase 1 Clinical Trials in Honduras: A Step-by-Step Guide

    Introduction

    Phase 1 clinical trials in Honduras offer MedTech and Biopharma companies a strategic advantage in accelerating research timelines. With a regulatory framework overseen by the Agencia de Regulación Sanitaria (ARSA) and the potential for expedited patient recruitment, sponsors can leverage the benefits of conducting early feasibility studies in this region.

    However, navigating these regulations can be daunting for many companies. Understanding the specific compliance requirements and documentation needed is crucial for ensuring a successful trial.

    Are you ready to tackle these regulatory pathways for quicker access to vital clinical data?

    Understand the Regulatory Landscape for Phase 1 Trials in Honduras

    Understanding the regulatory landscape in Honduras is crucial for the success of the phase 1 clinical trial Honduras, especially given the complexities involved. To navigate this environment effectively, it’s essential to comprehend the regulatory framework overseen by the Agencia de Regulación Sanitaria (ARSA). Here are the key steps:

    1. Familiarize with ARSA Requirements: Begin by reviewing the guidelines established by ARSA, which oversees the approval of clinical studies in Honduras. This includes understanding the necessary documentation and ethical considerations.
    2. Obtain Ethical Approval: Before commencing a study, securing approval from an Institutional Ethics Committee (IEC) that operates under ISO 14155 and the Declaration of Helsinki is vital. This ensures that the rights and welfare of participants are protected.
    3. Prepare for Submission: Compile all required documents, including the study protocol, investigator’s brochure, and informed consent forms. Are these documents clear and complete enough to meet ARSA’s standards?
    4. Submission Pathways: Submit your application through ARSA’s online portal. The review process generally takes between 30 to 90 days, depending on the complexity of the study and the responsiveness of the oversight body.
    5. Adherence to ICH-GCP: Ensure that your study complies with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) guidelines, which are crucial for upholding high-quality standards in research.

    Navigating the regulatory landscape can be daunting for sponsors, especially in a unique environment like Honduras. Ultimately, a thorough understanding of these regulatory steps can significantly impact the success of phase 1 clinical trial Honduras.

    Each box represents a step in the regulatory process for clinical trials. Follow the arrows to see how to navigate from understanding requirements to ensuring compliance with international standards.

    Prepare Required Documentation and Preclinical Data

    Preparing for a phase 1 clinical trial in Honduras requires meticulous attention to detail and a strategic approach to documentation. To ensure success, follow these essential steps:

    1. Compile Preclinical Information: Gather all relevant preclinical information that demonstrates the safety and efficacy of the investigational product. This should include toxicology studies, pharmacokinetic data, and any relevant previous clinical findings.
    2. Draft the Study Protocol: Create a detailed study protocol that clearly defines the objectives, design, methodology, and statistical analysis plan of the research. Ensure that it adheres to the requirements set forth by the ARSA (Agencia Reguladora de Salud de Honduras) and aligns with ICH-GCP guidelines.
    3. Prepare the Investigator’s Brochure: Develop an investigator’s brochure that provides comprehensive information about the investigational product, including its mechanism of action, dosing regimen, and potential risks associated with participation in the study.
    4. Informed Consent Forms: Draft clear and concise informed consent documents that effectively communicate the study’s purpose, procedures, risks, and benefits to potential participants. These forms must receive approval from the Institutional Ethics Committee (IEC).
    5. Regulatory Submission Package: Assemble all documents into a regulatory submission package, ensuring that each document is complete and formatted according to ARSA’s guidelines. This package will be submitted for review and approval.

    Navigating the complexities of regulatory requirements can be daunting for sponsors. However, by meticulously preparing these documents, sponsors can not only enhance their chances of approval but also expedite access to vital data. Ultimately, thorough preparation can be the key to unlocking faster access to critical clinical data.

    Each box represents a crucial step in preparing for the clinical trial. Follow the arrows to see how each step leads to the next, ensuring all necessary documentation is completed in order.

    Implement Effective Site Selection and Patient Recruitment Strategies

    Effective site selection and patient recruitment are not just important; they are the backbone of successful Phase 1 studies in clinical research. Here’s a structured approach to implement these strategies, leveraging the unique advantages of conducting trials in Latin America:

    1. Identify Suitable Research Sites: Evaluate potential research locations based on their experience with Phase 1 trials, patient demographics, and historical performance metrics. Prioritize sites that have successfully conducted similar studies, ensuring they are familiar with local regulatory requirements, such as those set by INVIMA.
    2. Engage with Investigators: Cultivate relationships with principal investigators who have a strong track record in research involving human subjects. Their expertise and dedication can greatly improve patient recruitment and ensure smooth execution of the study. At bioaccess®, our founders, including a Harvard-trained interventional cardiologist and a pioneer in cardiovascular medicine, bring unmatched clinical excellence to the forefront, ensuring that our investigators are well-prepared to lead these studies.
    3. Utilize Patient Databases: Leverage local patient databases and registries to identify potential participants who meet the study’s inclusion criteria. This targeted approach can streamline the recruitment process and improve enrollment rates, particularly in regions where treatment-naïve patient populations are abundant.
    4. Implement Targeted Outreach: Develop outreach campaigns that utilize social media, local healthcare providers, and community organizations to raise awareness about the study. Customized communication can effectively draw suitable participants, especially in areas where awareness of research studies is limited. We’ve seen firsthand how these strategies can accelerate recruitment for MedTech and Biopharma companies, often resulting in cost savings of about 30% compared to US/EU benchmarks.
    5. Monitor Recruitment Progress: Continuously track recruitment efforts and adjust strategies as necessary. Employ data analytics to evaluate recruitment trends and identify barriers that may impede enrollment, ensuring timely adjustments to maintain momentum. Many sponsors face significant challenges in meeting enrollment timelines, risking costly delays. Proactive oversight is crucial to prevent these setbacks.

    By implementing these strategies, sponsors can enhance site selection and patient recruitment, resulting in a more efficient and successful Phase 1 clinical trial in Honduras. With bioaccess®’s expertise and dedication to connecting medical innovation with research potential in Latin America, companies can anticipate commencing first-in-human studies within 6-8 weeks and obtaining FDA-bridgeable data roughly 40% quicker than US/EU routes. Furthermore, client testimonials from successful experiences with companies like Mitralign and ClarVista Medical highlight the effectiveness of our approach. With the right strategies in place, sponsors can transform their approach to clinical trials, ensuring timely and efficient outcomes that drive innovation forward.

    Each box in the flowchart represents a key step in the process of selecting research sites and recruiting patients for clinical trials. Follow the arrows to see how each step leads to the next, ultimately aiming for successful Phase 1 studies.

    Monitor and Manage Trial Progress for Compliance and Success

    To ensure the success of the phase 1 clinical trial in Honduras, meticulous monitoring and management of trial progress are non-negotiable. Follow these steps:

    1. Establish a Monitoring Plan: Develop a comprehensive monitoring plan that outlines the frequency and methods of monitoring activities, including site visits, data verification, and compliance checks. Ensure alignment with ICH-GCP guidelines and local compliance requirements set by INVIMA and ANVISA.
    2. Conduct Regular Site Visits: Schedule regular site visits to assess compliance with the study protocol and regulatory requirements. Use these visits to offer assistance, resolve concerns, and ensure that the site is prepared to achieve study objectives. When you monitor sites effectively, you can really cut down on compliance issues and boost the integrity of the study.
    3. Information Management: Implement robust information management practices to ensure the accuracy and integrity of trial results. This encompasses regular audits of entry processes, monitoring for discrepancies, and ensuring compliance with FDA acceptance criteria for submissions. Targeted monitoring strategies can lead to improved data quality while optimizing resource allocation.
    4. Address Compliance Issues: Proactively identify and address any compliance issues that may arise during the trial. This may involve corrective actions, additional training for site staff, or protocol amendments to align with evolving compliance standards. Compliance issues can derail a trial’s success, leading to delays and increased costs. Trial monitoring is crucial for ensuring the safety and rights of study participants.
    5. Communicate with Stakeholders: Maintain open lines of communication with all stakeholders, including investigators, sponsors, and oversight bodies. Regular updates on study progress and challenges faced will promote collaboration and transparency, which are crucial for navigating the regulatory landscape in the phase 1 clinical trial in Honduras.

    By keeping a close eye on study progress, sponsors not only ensure adherence but also uphold the integrity of the information. This approach is key to achieving the study’s objectives. Leveraging the strategic advantages of conducting clinical trials in Latin America, such as faster approval timelines and cost efficiency, bioaccess® enables MedTech and Biopharma companies to initiate first-in-human trials within 6-8 weeks and deliver FDA-bridgeable data approximately 40% faster than US/EU pathways.

    Each box represents a crucial step in ensuring the success of the clinical trial. Follow the arrows to see how each step connects to the next, guiding you through the process of maintaining compliance and achieving study objectives.

    Conclusion

    While navigating Phase 1 clinical trials in Honduras can be challenging, it also opens doors to significant opportunities for MedTech and Biopharma companies. By understanding the regulatory landscape, preparing meticulous documentation, and implementing effective site selection and patient recruitment strategies, sponsors can significantly enhance their chances of success. Honduras offers streamlined processes and cost efficiencies that speed up trial initiation and provide access to treatment-naïve patient populations, making it a compelling choice for first-in-human studies.

    Key insights from this guide emphasize the importance of:

    • Adhering to local regulations set forth by the Agencia de Regulación Sanitaria (ARSA)
    • Ensuring compliance with ICH-GCP standards
    • Engaging with experienced investigators
    • Utilizing targeted recruitment strategies

    By following these insights, sponsors can optimize their trial outcomes. Moreover, the ability to initiate trials within 6-8 weeks and deliver FDA-bridgeable data approximately 40% faster than traditional US/EU pathways underscores the competitive edge that conducting trials in Honduras offers.

    In conclusion, there’s a tremendous opportunity for success in Phase 1 clinical trials in Honduras. By embracing the outlined strategies and leveraging the expertise of specialized organizations like bioaccess®, companies can not only navigate the regulatory landscape effectively but also drive innovation forward in the MedTech and Biopharma sectors. Seize this moment to redefine your clinical trial strategy and harness the potential of Latin America for groundbreaking research.

    Frequently Asked Questions

    What is the role of the Agencia de Regulación Sanitaria (ARSA) in phase 1 clinical trials in Honduras?

    ARSA oversees the approval of clinical studies in Honduras, establishing the regulatory framework that must be followed for successful trial execution.

    What are the initial steps to take before starting a phase 1 clinical trial in Honduras?

    The initial steps include familiarizing yourself with ARSA requirements, obtaining ethical approval from an Institutional Ethics Committee (IEC), and preparing all necessary documentation.

    What ethical guidelines must be followed for phase 1 trials in Honduras?

    Ethical approval must be secured from an IEC that operates under ISO 14155 and the Declaration of Helsinki to ensure the protection of participants’ rights and welfare.

    What documents are required for submission to ARSA?

    Required documents include the study protocol, investigator’s brochure, and informed consent forms, all of which must meet ARSA’s standards for clarity and completeness.

    How is the submission process conducted for phase 1 trials in Honduras?

    Applications must be submitted through ARSA’s online portal, and the review process typically takes between 30 to 90 days, depending on the study’s complexity and the oversight body’s responsiveness.

    What guidelines must be adhered to during the clinical trial?

    The study must comply with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) guidelines to maintain high-quality research standards.

    Why is understanding the regulatory landscape important for phase 1 clinical trials in Honduras?

    A thorough understanding of the regulatory steps can significantly impact the success of the phase 1 clinical trial, helping sponsors navigate the complexities of the environment effectively.

    List of Sources

    1. Understand the Regulatory Landscape for Phase 1 Trials in Honduras
      • Pharmacovigilance in Honduras | Tepsivo (https://tepsivo.com/local-pharmacovigilance/honduras)
      • Master FIH Clinical Trials in Honduras: A Step-by-Step Guide – cms.bioaccessla.com (https://cms.bioaccessla.com/blog/master-fih-clinical-trials-in-honduras-a-step-by-step-guide)
      • Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC9658046)
      • Best Practices for EFS Clinical Trials in Honduras: Key Insights – cms.bioaccessla.com (https://cms.bioaccessla.com/blog/best-practices-for-efs-clinical-trials-in-honduras-key-insights)
    2. Prepare Required Documentation and Preclinical Data
      • What differentiates clinical trial statistics from preclinical methods and why robust approaches matter – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11327279)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • First-In-Human Clinical Trial Requirement -BioPharma Services (https://biopharmaservices.com/blog/phase-1-which-requirements-must-be-met-to-conduct-first-in-human-clinical-trials)
    3. Implement Effective Site Selection and Patient Recruitment Strategies
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Effective Strategies for Clinical Trial Patient Recruitment (https://milo-healthcare.com/en/effective-strategies-for-clinical-trial-patient-recruitment)
      • Recruiting Clinical Trial Participants: How to Balance Data and Trust | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/recruiting-clinical-trial-participants-how-to-balance-data-and-trust)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • The Importance of Patient Recruitment in Clinical Trials | Novotech CRO (https://novotech-cro.com/blog/importance-patient-recruitment-clinical-trials)
    4. Monitor and Manage Trial Progress for Compliance and Success
      • Clinical trial monitoring | MED Institute (https://medinstitute.com/blog/clinical-trial-monitoring)
      • Site Monitoring in Clinical Research | CCRPS (https://ccrps.org/clinical-research-blog/site-monitoring-in-clinical-research)
      • Clinical trials monitoring toolkit | UCL Innovative Clinical Trials Unit (https://innovative-ctu.ucl.ac.uk/our-research/methodology/conduct/clinical-trials-monitoring-toolkit)
      • Monitoring strategies for clinical intervention studies – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC8653423)
      • Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC6236642)